You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDexamethasone
Accession NumberDB01234  (APRD00674)
TypeSmall Molecule
GroupsApproved, Investigational, Vet Approved
DescriptionAn anti-inflammatory 9-fluoro-glucocorticoid. [PubChem]
Structure
Thumb
Synonyms
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16α-Methyl-9α-fluoro-1-dehydrocortisol
9alpha-Fluoro-16alpha-methylprednisolone
9α-Fluoro-16α-methylprednisolone
Decadron
Dexametasona
Dexamethasone
Dexamethasonum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Accufix II Dec Model 033-212Implant.7 mgIntracardiacTelectronics Pacing Systems Inc.1994-12-311999-08-27Canada
Decadron Phosphate Eye Ear Sol 0.1%Liquid1 mgAuricular (otic); OphthalmicMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1960-12-311998-04-21Canada
Decadron Phosphate Inj 4mg/mlLiquid4 mgIntramuscular; IntravenousMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1959-12-312001-08-01Canada
Decadron Tab 0.5mgTablet.5 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1958-12-312002-07-29Canada
Decadron Tab 4mgTablet4 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1976-12-312003-08-08Canada
Dexamethasone Omega UnidoseSolution10 mgIntramuscular; Intrasynovial; IntravenousOmega Laboratories Ltd2013-05-08Not applicableCanada
Dexamethasone Sod Phos Inj 4mg/mlLiquid4 mgIntramuscular; IntravenousTaro Pharmaceuticals Inc1989-12-312001-08-21Canada
Dexamethasone Sod Phosph Inj 10mg/ml USPLiquid10 mgIntramuscular; Intrasynovial; IntravenousSandoz Canada Incorporated1990-12-31Not applicableCanada
Dexamethasone Sodium Phosphate 0.1%Solution / drops.1 %Auricular (otic); OphthalmicRivex Ophthalmics Inc.1997-05-072003-07-28Canada
Dexamethasone Sodium Phosphate Inj USP 4mg/mlSolution4 mgIntramuscular; Intrasynovial; IntravenousSandoz Canada Incorporated1986-12-31Not applicableCanada
Dexamethasone Sodium Phosphate Injection SdzSolution4 mgIntramuscular; Intrasynovial; IntravenousSandoz Canada IncorporatedNot applicableNot applicableCanada
Dexamethasone Sodium Phosphate Injection SdzSolution10 mgIntramuscular; Intrasynovial; IntravenousSandoz Canada IncorporatedNot applicableNot applicableCanada
Dexamethasone Sodium Phosphate Injection, USPLiquid4 mgIntra-articular; Intramuscular; IntravenousSterimax Inc1992-12-31Not applicableCanada
Dexamethasone Sodium Phosphate Injection, USPSolution4 mgIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissueMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Dexamethasone Sodium Phosphate Injection, USPSolution10 mgIntramuscular; IntravenousMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Dexamethasone-omegaLiquid10 mgIntramuscular; IntravenousOmega Laboratories Ltd1999-06-30Not applicableCanada
Dexamethasone-omegaLiquid4 mgIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissueOmega Laboratories Ltd1999-04-01Not applicableCanada
Dexasone 0.5mgTablet0.5 mgOralValeant Canada Lp Valeant Canada S.E.C.1974-12-312014-07-30Canada
Dexasone 0.75mgTablet0.75 mgOralValeant Canada Lp Valeant Canada S.E.C.1974-12-312014-07-30Canada
Dexasone 4mgTablet4 mgOralValeant Canada Lp/valeant Canada s.e.c.1979-12-312016-07-08Canada
Diodex Solution 0.1%Solution0.1 %Auricular (otic); OphthalmicDioptic Pharmaceuticals Inc1994-12-31Not applicableCanada
Dom-dexamethasone Tablet 4mgTablet4 mgOralDominion Pharmacal1999-03-04Not applicableCanada
Encor Dec Model 033-159 Imp 0.5mg/impImplant.5 mgIntracardiacTelectronics Pacing Systems Inc.1994-12-311999-08-27Canada
Encor Dec Model 033-443 Imp 0.5mg/impImplant.5 mgIntracardiacTelectronics Pacing Systems Inc.1994-12-311999-08-27Canada
Encor Dec Model 033-448 Imp 0.5mg/impImplant.5 mgIntracardiacTelectronics Pacing Systems Inc.1994-12-311999-08-27Canada
Encor Dec Model 033-757 Imp 0.5mg/impImplant0.5 mgIntracardiacTelectronics Pacing Systems Inc.1994-12-311996-09-10Canada
Encor Dec Model 033-856 Imp 0.5mg/impImplant.5 mgIntracardiacTelectronics Pacing Systems Inc.1994-12-311996-09-10Canada
Hexadrol Phosphate Inj 10mg/mlLiquid10 mgIntramuscular; IntravenousOrganon Teknika Canada Inc.1987-12-312001-09-18Canada
Hexadrol Phosphate Inj 4mg/mlLiquid4 mgIntramuscular; IntravenousOrganon Teknika Canada Inc.1987-12-312001-09-18Canada
MaxidexSuspension1 mg/mLOphthalmicAlcon Laboratories, Inc.1966-05-15Not applicableUs
Maxidex Ont 0.1%Ointment0.1 %OphthalmicAlcon Canada Inc1966-12-31Not applicableCanada
Maxidex Sus 0.1%Solution / drops0.1 %OphthalmicAlcon Canada Inc1977-12-31Not applicableCanada
NeofordexTablet40 mgOralLaboratoires Ctrs2016-03-16Not applicableEu
Ocudex Liq 0.1%Liquid.1 %Ophthalmic; TopicalHerdt Et Charton Inc.1994-12-311999-09-17Canada
Odan-dexamethasoneSolution0.1 %Auricular (otic); OphthalmicOdan Laboratories Ltd1985-12-31Not applicableCanada
OzurdexImplant.7 mg/1IntravitrealAllergan, Inc.2009-09-01Not applicableUs
OzurdexImplant0.7 mgIntravitrealAllergan Inc2011-06-02Not applicableCanada
OzurdexImplant700 microIntravitrealAllergan Pharmaceuticals Ireland2010-07-27Not applicableEu
PHL-dexamethasoneTablet4 mgOralPharmel Inc1998-02-17Not applicableCanada
PHL-dexamethasoneElixir0.5 mgOralPharmel Inc2004-12-06Not applicableCanada
PHL-dexamethasoneTablet0.5 mgOralPharmel Inc1998-02-17Not applicableCanada
PHL-dexamethasoneLiquid10 mgIntramuscular; IntravenousPharmel Inc2004-12-06Not applicableCanada
PHL-dexamethasoneTablet0.75 mgOralPharmel Inc1998-02-17Not applicableCanada
PMS Dexamethasone Elixir 0.5mg/5mlLiquid0.5 mgOralPharmascience Inc1992-12-31Not applicableCanada
PMS Dexamethasone Tab 0.5mg USPTablet0.5 mgOralPharmascience Inc1996-08-26Not applicableCanada
PMS Dexamethasone Tab 0.75mg USPTablet0.75 mgOralPharmascience Inc1996-09-05Not applicableCanada
PMS Dexamethasone Tab 4mgTablet4 mgOralPharmascience Inc1996-09-05Not applicableCanada
PMS-dexamethasoneTablet2 mgOralPharmascience Inc2006-06-08Not applicableCanada
PMS-dexamethasone Sod Phosphate Dps 1mg/mlSolution / drops1 mgAuricular (otic); OphthalmicPharmascience Inc1989-12-31Not applicableCanada
PMS-dexamethasone Sod Phosphate Inj 10mg/mlLiquid10 mgIntramuscular; IntravenousPharmascience Inc1990-12-31Not applicableCanada
PMS-dexamethasone Sod Phosphate Inj 4mg/mlSolution4 mgIntra-articular; Intramuscular; IntravenousPharmascience Inc1989-12-31Not applicableCanada
Pro-dexamethasone - 4Tablet4 mgOralPro Doc Limitee2008-07-04Not applicableCanada
R.O.-dexsoneSolution / drops.1 %Auricular (otic); OphthalmicRichmond Pharmaceuticals Inc.1992-12-311997-08-11Canada
Ratio-dexamethasoneTablet0.5 mgOralTeva Canada Limited1999-10-29Not applicableCanada
Ratio-dexamethasoneTablet4 mgOralTeva Canada Limited1999-10-29Not applicableCanada
Ratio-dexamethasone Tablets, USPTablet0.75 mgOralRatiopharm Inc Division Of Teva Canada Limited1999-10-292009-07-17Canada
Sandoz DexamethasoneSolution / drops1 mgAuricular (otic); OphthalmicSandoz Canada Incorporated1990-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-dexamethasoneTablet4 mgOralApotex Inc2004-03-08Not applicableCanada
Apo-dexamethasoneTablet0.5 mgOralApotex Inc2004-11-17Not applicableCanada
BaycadronElixir.5 mg/5mLOralWockhardt USA, LLC1983-07-27Not applicableUs
DexamethasoneTablet4 mg/1Oralbryant ranch prepack1978-07-19Not applicableUs
DexamethasoneTablet.75 mg/1OralPreferred Pharmaceuticals, Inc.2012-01-17Not applicableUs
DexamethasoneTablet1 mg/1OralWest Ward Pharmaceuticals Corp.1983-09-15Not applicableUs
DexamethasoneTablet4 mg/1OralA S Medication Solutions Llc1983-04-28Not applicableUs
DexamethasoneTablet4 mg/1OralPhysicians Total Care, Inc1994-01-19Not applicableUs
DexamethasoneTablet.5 mg/1OralWest Ward Pharmaceuticals Corp.1975-07-25Not applicableUs
DexamethasoneTablet1.5 mg/1OralECR Pharmaceuticals2000-04-01Not applicableUs
DexamethasoneTablet4 mg/1OralPar Pharmaceutical Inc.1983-04-28Not applicableUs
DexamethasoneTablet2 mg/1OralProficient Rx LP1982-08-26Not applicableUs
DexamethasoneTablet.75 mg/1OralA S Medication Solutions Llc1975-06-03Not applicableUs
DexamethasoneElixir.5 mg/5mLOralRising Pharmaceuticals, Inc.2011-08-01Not applicableUs
DexamethasoneTablet.75 mg/1OralWest Ward Pharmaceuticals Corp.1975-06-03Not applicableUs
DexamethasoneTablet2 mg/1OralPd Rx Pharmaceuticals, Inc.1982-08-26Not applicableUs
DexamethasoneTablet4 mg/1OralA S Medication Solutions Llc1978-07-19Not applicableUs
DexamethasoneTablet4 mg/1OralRebel Distributors Corp1978-07-19Not applicableUs
DexamethasoneTablet2 mg/1OralWest Ward Pharmaceuticals Corp.1982-08-26Not applicableUs
DexamethasoneElixir.5 mg/5mLOralCardinal Health1983-07-27Not applicableUs
DexamethasoneTablet1.5 mg/1Oralbryant ranch prepack2006-07-07Not applicableUs
DexamethasoneElixir.5 mg/5mLOralSTI Pharma LLC1976-09-21Not applicableUs
DexamethasoneTablet4 mg/1OralWest Ward Pharmaceuticals Corp.1978-07-19Not applicableUs
DexamethasoneTablet.75 mg/1OralPd Rx Pharmaceuticals, Inc.1975-06-03Not applicableUs
DexamethasoneTablet.75 mg/1OralPhysicians Total Care, Inc1996-05-10Not applicableUs
DexamethasoneTablet1.5 mg/1OralECR Pharmaceuticals2009-04-01Not applicableUs
DexamethasoneTablet4 mg/1OralAidarex Pharmaceuticals LLC1983-04-28Not applicableUs
DexamethasoneElixir.5 mg/5mLOralSTI Pharma LLC1976-09-21Not applicableUs
DexamethasoneElixir.5 mg/5mLOralMorton Grove Pharmaceuticals, Inc.1983-07-27Not applicableUs
DexamethasoneTablet.75 mg/1OralWest Ward Pharmaceuticals Corp.1975-06-03Not applicableUs
DexamethasoneTablet1.5 mg/1OralECR Pharmaceuticals2009-04-01Not applicableUs
DexamethasoneTablet6 mg/1OralPar Pharmaceutical Inc.1983-11-28Not applicableUs
DexamethasoneTablet4 mg/1OralNu Care Pharmaceuticals, Inc.1983-04-28Not applicableUs
DexamethasoneTablet4 mg/1OralA S Medication Solutions Llc1978-07-19Not applicableUs
DexamethasoneTablet1.5 mg/1OralWest Ward Pharmaceuticals Corp.1975-05-19Not applicableUs
DexamethasoneTablet2 mg/1OralPhysicians Total Care, Inc2005-06-21Not applicableUs
DexamethasoneTablet.5 mg/1OralPar Pharmaceutical Inc.1983-04-28Not applicableUs
DexamethasoneTablet4 mg/1OralDispensing Solutions, Inc.1978-07-19Not applicableUs
DexamethasoneTablet4 mg/1OralWest Ward Pharmaceuticals Corp.1978-07-19Not applicableUs
DexamethasoneTablet4 mg/1OralCardinal Health2011-06-29Not applicableUs
DexamethasoneTablet4 mg/1OralA S Medication Solutions Llc1978-07-19Not applicableUs
DexamethasoneTablet1 mg/1OralRebel Distributors Corp1983-09-15Not applicableUs
DexamethasoneTablet.75 mg/1Oralbryant ranch prepack1975-06-03Not applicableUs
DexamethasoneTablet2 mg/1OralWest Ward Pharmaceuticals Corp.1982-08-26Not applicableUs
DexamethasoneTablet1.5 mg/1OralDIRECT RX2015-01-01Not applicableUs
DexamethasoneTablet.5 mg/1OralPhysicians Total Care, Inc2009-01-28Not applicableUs
DexamethasoneTablet4 mg/1OralSTAT Rx USA LLC1978-07-19Not applicableUs
DexamethasoneTablet1 mg/1OralWest Ward Pharmaceuticals Corp.1983-09-15Not applicableUs
DexamethasoneTablet4 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC1978-07-19Not applicableUs
DexamethasoneElixir.5 mg/5mLOralQualitest Pharmaceuticals2011-05-112017-07-31Us
DexamethasoneTablet2 mg/1OralA S Medication Solutions Llc1982-08-26Not applicableUs
DexamethasoneTablet6 mg/1OralWest Ward Pharmaceuticals Corp.1983-09-15Not applicableUs
DexamethasoneTablet.75 mg/1OralH.J. Harkins Company, Inc.1983-04-28Not applicableUs
DexamethasoneTablet1.5 mg/1OralPhysicians Total Care, Inc.2005-06-13Not applicableUs
DexamethasoneTablet1.5 mg/1OralBlenheim Pharmacal, Inc.2013-12-10Not applicableUs
DexamethasoneTablet.75 mg/1OralPar Pharmaceutical Inc.1983-04-28Not applicableUs
DexamethasoneTablet4 mg/1OralPreferred Pharmaceuticals, Inc.2012-01-17Not applicableUs
DexamethasoneTablet6 mg/1OralWest Ward Pharmaceuticals Corp.1983-09-15Not applicableUs
DexamethasoneTablet2 mg/1OralCardinal Health2011-06-29Not applicableUs
DexamethasoneTablet4 mg/1OralA S Medication Solutions Llc1983-04-28Not applicableUs
DexamethasoneTablet4 mg/1OralProficient Rx LP1978-07-19Not applicableUs
DexamethasoneTablet4 mg/1OralA S Medication Solutions Llc1978-07-19Not applicableUs
DexamethasoneTablet2 mg/1OralRebel Distributors Corp1982-08-26Not applicableUs
DexamethasoneTablet.5 mg/1OralWest Ward Pharmaceuticals Corp.1975-07-25Not applicableUs
DexamethasoneTablet1.5 mg/1OralPhysicians Total Care, Inc1996-06-21Not applicableUs
DexamethasoneTablet.75 mg/1OralRebel Distributors Corp1975-06-03Not applicableUs
DexamethasoneTablet1.5 mg/1OralWest Ward Pharmaceuticals Corp.1975-05-19Not applicableUs
DexamethasoneTablet.75 mg/1OralA S Medication Solutions Llc1983-04-28Not applicableUs
DexamethasoneTablet4 mg/1OralPd Rx Pharmaceuticals, Inc.1978-07-19Not applicableUs
DexamethasoneSolution.5 mg/5mLOralWest Ward Pharmaceuticals Corp.1983-09-01Not applicableUs
DexamethasoneTablet1.5 mg/1OralECR Pharmaceuticals2006-09-01Not applicableUs
DexamethasoneTablet4 mg/1OralH.J. Harkins Company, Inc.1983-04-28Not applicableUs
DexamethasoneTablet6 mg/1OralPhysicians Total Care, Inc2008-05-30Not applicableUs
DexamethasoneTablet4 mg/1OralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
DexamethasoneTablet1.5 mg/1OralPar Pharmaceutical Inc.1983-04-28Not applicableUs
Dexamethasone IntensolSolution, concentrate1 mg/mLOralWest Ward Pharmaceuticals Corp.1983-09-01Not applicableUs
Dexamethasone IntensolSolution, concentrate1 mg/mLOralCarilion Materials Management1983-09-01Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissueCardinal Health2011-05-11Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissueCardinal Health2011-05-11Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntramuscular; IntravenousREMEDYREPACK INC.2016-11-04Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissuePfizer Laboratories Div Pfizer Inc2011-05-11Not applicableUs
Dexamethasone Sodium PhosphateSolution1 mg/mLOphthalmicRebel Distributors Corp1985-01-16Not applicableUs
Dexamethasone Sodium PhosphateInjection10 mg/mLIntramuscular; IntravenousPhysicians Total Care, Inc.2010-01-15Not applicableUs
Dexamethasone Sodium PhosphateSolution / drops1 mg/mLOphthalmicPhoenix Pharmaceutical, Inc.1996-07-26Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution10 mg/mLIntramuscular; IntravenousMylan Institutional LLC2011-05-11Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution10 mg/mLIntramuscular; IntravenousPfizer Laboratories Div Pfizer Inc2011-05-11Not applicableUs
Dexamethasone Sodium PhosphateSolution / drops1 mg/mLOphthalmicButler Animal Health Supply1996-07-26Not applicableUs
Dexamethasone Sodium PhosphateSolution1 mg/mLOphthalmicPhysicians Total Care, Inc.2005-06-20Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissueAmerican Regent, Inc.1990-09-302016-11-10Us
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntravenousREMEDYREPACK INC.2013-08-132016-10-13Us
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntramuscular; IntravenousCardinal Health2000-09-07Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissueGeneral Injectables and Vaccines, Inc2016-02-18Not applicableUs
Dexamethasone Sodium PhosphateInjection4 mg/mLIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissueWest Ward Pharmaceuticals Corp.1975-07-15Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntra-articular; Intramuscular; IntravenousGeneral Injectables and Vaccines, Inc2015-08-21Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntramuscular; IntravenousA S Medication Solutions Llc2000-09-07Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution10 mg/mLIntramuscular; IntravenousPfizer Laboratories Div Pfizer Inc2011-05-11Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissueAuro Medics Pharma Llc2015-12-01Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntramuscular; IntravenousFresenius Kabi USA, LLC2000-09-07Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution10 mg/mLIntramuscular; IntravenousMylan Institutional LLC2011-05-11Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissueA S Medication Solutions2011-05-11Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissueMylan Institutional LLC2011-05-11Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissuePfizer Laboratories Div Pfizer Inc2011-05-11Not applicableUs
Dexamethasone Sodium PhosphateSolution / drops1 mg/mLOphthalmicStat Rx USA1996-07-26Not applicableUs
Dexamethasone Sodium PhosphateInjection4 mg/mLIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissueWest Ward Pharmaceuticals Corp.1975-07-15Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution10 mg/mLIntramuscular; IntravenousGeneral Injectables & Vaccines, Inc2010-08-01Not applicableUs
Dexamethasone Sodium PhosphateSolution / drops1 mg/mLOphthalmicMajor Pharmaceuticals1996-07-26Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution10 mg/mLIntramuscular; IntravenousCardinal Health2003-05-29Not applicableUs
Dexamethasone Sodium PhosphateInjection10 mg/mLIntramuscular; IntravenousGENERAL INJECTABLES AND VACCINES, INC.2014-05-26Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissueMylan Institutional LLC2011-05-11Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissueBD Rx Inc.2015-10-30Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntramuscular; IntravenousA S Medication Solutions Llc2000-09-07Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissuePfizer Laboratories Div Pfizer Inc2011-05-11Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissueAuro Medics Pharma Llc2015-12-01Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution10 mg/mLIntramuscular; IntravenousFresenius Kabi USA, LLC2003-05-29Not applicableUs
Dexamethasone Sodium PhosphateSolution / drops1 mg/mLOphthalmicRebel Distributors Corp1996-07-26Not applicableUs
Dexamethasone Sodium PhosphateInjection10 mg/mLIntramuscular; IntravenousCardinal Health1982-09-07Not applicableUs
Dexamethasone Sodium PhosphateInjection10 mg/mLIntramuscularREMEDYREPACK INC.2013-08-13Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution10 mg/mLIntramuscular; IntravenousA S Medication Solutions2003-05-29Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissueAmerican Regent, Inc.1990-09-302016-11-10Us
Dexamethasone Sodium PhosphateSolution1 mg/mLOphthalmicDispensing Solutions, Inc.2004-07-01Not applicableUs
Dexamethasone Sodium PhosphateSolution1 mg/mLOphthalmicSandoz Inc2004-07-01Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissueMylan Institutional LLC2011-05-11Not applicableUs
Dexamethasone Sodium PhosphateInjection10 mg/mLIntramuscular; IntravenousWest Ward Pharmaceuticals Corp.1982-09-07Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissuePfizer Laboratories Div Pfizer Inc2011-05-11Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntramuscular; IntravenousA S Medication Solutions2000-09-07Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntramuscular; IntravenousCardinal Health2000-09-07Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissueMylan Institutional LLC2011-05-11Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution10 mg/mLIntramuscular; IntravenousFresenius Kabi USA, LLC2005-04-05Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissuePfizer Laboratories Div Pfizer Inc2011-05-11Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissueCardinal Health2011-05-11Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissueAmerican Regent, Inc.1990-09-302016-11-10Us
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntramuscularREMEDYREPACK INC.2013-11-182016-10-29Us
Dexamethasone Sodium PhosphateInjection4 mg/5mLIntra-articular; Intralesional; Intramuscular; IntravenousGeneral Injectables & Vaccines, Inc.2011-07-18Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissuePfizer Laboratories Div Pfizer Inc2011-05-11Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissueAuro Medics Pharma Llc2015-12-01Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntra-articularREMEDYREPACK INC.2015-07-17Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissueMylan Institutional LLC2011-05-11Not applicableUs
Dexamethasone Sodium PhosphateSolution / drops1 mg/mLOphthalmicBausch & Lomb Incorporated1996-07-26Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissueA S Medication Solutions2011-05-11Not applicableUs
Dexamethasone Sodium PhosphateSolution / drops1 mg/mLOphthalmicA S Medication Solutions Llc1996-07-26Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissueMylan Institutional LLC2011-05-11Not applicableUs
Dexamethasone Sodium PhosphateInjection, solution4 mg/mLIntramuscular; IntravenousA S Medication Solutions2000-09-07Not applicableUs
Dexamethasone Sodium PhosphatesInjection, solution4 mg/mLIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissueCardinal Health1990-09-30Not applicableUs
DexamethsoneTablet4 mg/1OralNorthwind Pharmaceuticals, LLC2014-08-11Not applicableUs
Readysharp DexamethasoneInjection10 mg/mLIntramuscular; IntravenousTerrain Pharmaceuticals1982-09-07Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DecadronSidus
Brand mixtures
NameLabellerIngredients
999 Itch ReliefChina Resources Sanjiu Medical & Pharmaceutical Co Ltd
CiprodexRebel Distributors Corp
Cresophene LiqSeptodont
Dioptrol OintmentDioptic Pharmaceuticals Inc
Dioptrol SuspensionDioptic Pharmaceuticals Inc
MaxitrolAlcon Laboratories, Inc.
Maxitrol OntAlcon Canada Inc
MethedexMajor Pharmaceuticals
Neo-poly-dexButler Animal Health Supply
Neodecadron Eye Ear Soln 0.1%Merck Frosst Canada & Cie, Merck Frosst Canada & Co.
Neomycin and Polymyxin B Sulfates and DexamethasonePaddock Laboratories, LLC
Neomycin Polymyxin B Sulfates and DexamethasoneMwi/Vet One
Neomycin Sulfate, Polymyxin B Sulfate and DexamethasoneSTAT RX LLC USA
NpdPhoenix Pharmaceutical, Inc.
Odan-trolOdan Laboratories Ltd
Sandoz OpticortSandoz Canada Incorporated
Sofracort Ear/eye OintmentRoussel Canada Inc.
Sofracort Sterile Ear/eye DropsSanofi Aventis Canada Inc
Sofracort Sterile Ear/eye OintmentHoechst Roussel Canada Inc.
TobradexAlcon Laboratories, Inc.
Tobradex Oph OintmentAlcon Canada Inc
Tobradex Oph SusAlcon Canada Inc
Tobradex STAlcon Laboratories, Inc.
Tobramycin and DexamethasoneRebel Distributors Corp
Salts
Name/CASStructureProperties
Dexamethasone acetate
1177-87-3
Thumb
  • InChI Key: AKUJBENLRBOFTD-RPRRAYFGSA-N
  • Monoisotopic Mass: 434.210466929
  • Average Mass: 434.4977
DBSALT000383
Dexamethasone phosphate
312-93-6
Thumb
  • InChI Key: VQODGRNSFPNSQE-CXSFZGCWSA-N
  • Monoisotopic Mass: 472.166232653
  • Average Mass: 472.441
DBSALT001216
Dexamethasone sodium phosphate
2392-39-4
Thumb
  • InChI Key: PLCQGRYPOISRTQ-FCJDYXGNSA-L
  • Monoisotopic Mass: 516.130121939
  • Average Mass: 516.4046
DBSALT000843
Categories
UNII7S5I7G3JQL
CAS number50-02-2
WeightAverage: 392.4611
Monoisotopic: 392.199902243
Chemical FormulaC22H29FO5
InChI KeyUREBDLICKHMUKA-CXSFZGCWSA-N
InChI
InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1
IUPAC Name
(1R,2S,10S,11S,13R,14R,15S,17S)-1-fluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES
[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[[email protected]](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Pharmacology
IndicationInjection: for the treatment of endocrine disorders, rheumatic D=disorders, collagen diseases, dermatologic diseases, allergic statesc, ophthalmic diseases, gastrointestinal diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, cerebral edema.
Ophthalmic ointment and solution: for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.
Ophthalmic solution only: for the treatment of steroid responsive inflammatory conditions of the external auditory meatus
Topic cream: for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses
Oral aerosol: for the treatment of bronchial asthma and related corticosteroid responsive bronchospastic states intractable to adequate trial of conventional therapy
Intranasal aerosol: for the treatment of allergic ot inflammatory nasal conditions, and nasal polyps
Structured Indications
PharmacodynamicsDexamethasone and its derivatives, dexamethasone sodium phosphate and dexamethasone acetate, are synthetic glucocorticoids. Used for its antiinflammatory or immunosuppressive properties and ability to penetrate the CNS, dexamethasone is used alone to manage cerebral edema and with tobramycin to treat corticosteroid-responsive inflammatory ocular conditions.
Mechanism of actionDexamethasone is a glucocorticoid agonist. Unbound dexamethasone crosses cell membranes and binds with high affinity to specific cytoplasmic glucocorticoid receptors. This complex binds to DNA elements (glucocorticoid response elements) which results in a modification of transcription and, hence, protein synthesis in order to achieve inhibition of leukocyte infiltration at the site of inflammation, interference in the function of mediators of inflammatory response, suppression of humoral immune responses, and reduction in edema or scar tissue. The antiinflammatory actions of dexamethasone are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
TargetKindPharmacological actionActionsOrganismUniProt ID
Glucocorticoid receptorProteinyes
agonist
HumanP04150 details
Nuclear receptor subfamily 0 group B member 1Proteinunknown
stimulator
HumanP51843 details
Annexin A1Proteinunknown
agonist
HumanP04083 details
Nitric oxide synthase, inducibleProteinunknown
negative modulator
HumanP35228 details
Related Articles
Absorption80-90%
Volume of distributionNot Available
Protein binding70%
Metabolism

Hepatic.

SubstrateEnzymesProduct
Dexamethasone
6-beta-hydroxydexamethasoneDetails
Route of eliminationNot Available
Half life36-54 hours
ClearanceNot Available
ToxicityOral, rat LD50: >3 gm/kg. Signs of overdose include retinal toxicity, glaucoma, subcapsular cataract, gastrointestinal bleeding, pancreatitis, aseptic bone necrosis, osteoporosis, myopathies, obesity, edemas, hypertension, proteinuria, diabetes, sleep disturbances, psychiatric syndromes, delayed wound healing, atrophy and fragility of the skin, ecchymosis, and pseudotumor cerebri.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with 1,10-Phenanthroline.Experimental
AbirateroneThe serum concentration of Abiraterone can be decreased when it is combined with Dexamethasone.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Dexamethasone.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Dexamethasone.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Dexamethasone.Approved
AcenocoumarolThe serum concentration of Acenocoumarol can be decreased when it is combined with Dexamethasone.Approved
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Dexamethasone.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Dexamethasone.Withdrawn
AcetovanilloneThe risk or severity of adverse effects can be increased when Acetovanillone is combined with Dexamethasone.Investigational
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Dexamethasone.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Dexamethasone.Approved
AdinazolamThe serum concentration of Adinazolam can be decreased when it is combined with Dexamethasone.Approved
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Dexamethasone.Approved
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Dexamethasone.Experimental
AlbendazoleThe serum concentration of Albendazole can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
AlclometasoneThe serum concentration of Alclometasone can be decreased when it is combined with Dexamethasone.Approved
AldesleukinDexamethasone may decrease the antineoplastic activities of Aldesleukin.Approved
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Dexamethasone.Experimental
AlectinibThe serum concentration of Dexamethasone can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Alfentanil can be decreased when it is combined with Dexamethasone.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be decreased when it is combined with Dexamethasone.Approved, Investigational
AliskirenThe serum concentration of Aliskiren can be decreased when it is combined with Dexamethasone.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Dexamethasone.Approved, Investigational
AllylestrenolThe serum concentration of Allylestrenol can be decreased when it is combined with Dexamethasone.Approved
AlmotriptanThe serum concentration of Almotriptan can be decreased when it is combined with Dexamethasone.Approved, Investigational
AlogliptinThe serum concentration of Alogliptin can be decreased when it is combined with Dexamethasone.Approved
AlosetronThe serum concentration of Alosetron can be decreased when it is combined with Dexamethasone.Approved, Withdrawn
AlprazolamThe serum concentration of Alprazolam can be decreased when it is combined with Dexamethasone.Approved, Illicit, Investigational
ALT-110The risk or severity of adverse effects can be increased when Dexamethasone is combined with ALT-110.Investigational
Aluminum hydroxideThe bioavailability of Dexamethasone can be decreased when combined with Aluminum hydroxide.Approved
Aluminum phosphateThe bioavailability of Dexamethasone can be decreased when combined with Aluminum phosphate.Approved
AmantadineThe serum concentration of Dexamethasone can be increased when it is combined with Amantadine.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Ambenonium.Approved
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Dexamethasone.Approved, Investigational
AmbroxolThe serum concentration of Ambroxol can be decreased when it is combined with Dexamethasone.Approved
Aminohippuric acidThe serum concentration of Dexamethasone can be increased when it is combined with Aminohippuric acid.Approved
AminophenazoneThe serum concentration of Aminophenazone can be decreased when it is combined with Dexamethasone.Approved, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Dexamethasone.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Dexamethasone.Approved
AmiodaroneThe metabolism of Dexamethasone can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Dexamethasone.Approved
AmlodipineThe serum concentration of Amlodipine can be decreased when it is combined with Dexamethasone.Approved
Amphotericin BDexamethasone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Amprenavir can be decreased when it is combined with Dexamethasone.Approved
AmsacrineThe serum concentration of Dexamethasone can be increased when it is combined with Amsacrine.Approved
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Dexamethasone.Investigational
AntipyrineThe serum concentration of Antipyrine can be decreased when it is combined with Dexamethasone.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Dexamethasone.Investigational
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Dexamethasone.Approved
ApremilastThe serum concentration of Apremilast can be decreased when it is combined with Dexamethasone.Approved, Investigational
AprepitantThe serum concentration of Dexamethasone can be increased when it is combined with Aprepitant.Approved, Investigational
ArgatrobanThe serum concentration of Argatroban can be decreased when it is combined with Dexamethasone.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Dexamethasone.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Dexamethasone.Approved, Investigational
ArtemetherThe serum concentration of Artemether can be decreased when it is combined with Dexamethasone.Approved
AsenapineThe serum concentration of Asenapine can be decreased when it is combined with Dexamethasone.Approved
AsparaginaseThe serum concentration of Dexamethasone can be increased when it is combined with Asparaginase.Approved
Asparaginase Erwinia chrysanthemiThe serum concentration of Dexamethasone can be increased when it is combined with Asparaginase Erwinia chrysanthemi.Approved
AstemizoleThe serum concentration of Astemizole can be decreased when it is combined with Dexamethasone.Approved, Withdrawn
AtazanavirThe metabolism of Dexamethasone can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Dexamethasone.Approved
AtomoxetineThe metabolism of Dexamethasone can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Dexamethasone.Approved
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Dexamethasone.Approved
AvanafilThe serum concentration of Avanafil can be decreased when it is combined with Dexamethasone.Approved
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Dexamethasone.Approved, Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Dexamethasone.Withdrawn
AzelastineThe serum concentration of Azelastine can be decreased when it is combined with Dexamethasone.Approved
AzithromycinThe serum concentration of Azithromycin can be decreased when it is combined with Dexamethasone.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Dexamethasone.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Dexamethasone.Approved, Investigational
BanoxantroneThe serum concentration of Banoxantrone can be decreased when it is combined with Dexamethasone.Investigational
BazedoxifeneThe serum concentration of Dexamethasone can be increased when it is combined with Bazedoxifene.Approved, Investigational
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Dexamethasone.Investigational
BedaquilineThe serum concentration of Bedaquiline can be decreased when it is combined with Dexamethasone.Approved
BendroflumethiazideDexamethasone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Dexamethasone.Withdrawn
BenzocaineThe serum concentration of Dexamethasone can be increased when it is combined with Benzocaine.Approved
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Dexamethasone.Approved
BenzphetamineThe serum concentration of Benzphetamine can be decreased when it is combined with Dexamethasone.Approved, Illicit
Benzyl alcoholThe serum concentration of Benzyl alcohol can be decreased when it is combined with Dexamethasone.Approved
BepridilThe serum concentration of Dexamethasone can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Dexamethasone.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Dexamethasone.Approved, Investigational
BexaroteneThe serum concentration of Dexamethasone can be decreased when it is combined with Bexarotene.Approved, Investigational
BezafibrateThe serum concentration of Bezafibrate can be decreased when it is combined with Dexamethasone.Approved
BicalutamideThe serum concentration of Bicalutamide can be decreased when it is combined with Dexamethasone.Approved
BiperidenThe serum concentration of Dexamethasone can be increased when it is combined with Biperiden.Approved
Bismuth SubcitrateThe bioavailability of Dexamethasone can be decreased when combined with Bismuth Subcitrate.Approved
BisoprololThe serum concentration of Bisoprolol can be decreased when it is combined with Dexamethasone.Approved
BoceprevirThe metabolism of Dexamethasone can be decreased when combined with Boceprevir.Approved
BortezomibThe serum concentration of Bortezomib can be decreased when it is combined with Dexamethasone.Approved, Investigational
BosentanThe serum concentration of Dexamethasone can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Dexamethasone.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Dexamethasone.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be decreased when it is combined with Dexamethasone.Approved
BrinzolamideThe serum concentration of Brinzolamide can be decreased when it is combined with Dexamethasone.Approved
BromazepamThe serum concentration of Bromazepam can be decreased when it is combined with Dexamethasone.Approved, Illicit
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Dexamethasone.Approved
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Dexamethasone.Approved, Investigational
BrompheniramineThe serum concentration of Brompheniramine can be decreased when it is combined with Dexamethasone.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Dexamethasone.Investigational
BudesonideThe serum concentration of Budesonide can be decreased when it is combined with Dexamethasone.Approved
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Dexamethasone.Withdrawn
BumetanideDexamethasone may increase the hypokalemic activities of Bumetanide.Approved
BupivacaineThe serum concentration of Bupivacaine can be decreased when it is combined with Dexamethasone.Approved, Investigational
BuprenorphineThe serum concentration of Buprenorphine can be decreased when it is combined with Dexamethasone.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Bupropion can be decreased when it is combined with Dexamethasone.Approved
BuspironeThe serum concentration of Buspirone can be decreased when it is combined with Dexamethasone.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be decreased when it is combined with Dexamethasone.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Dexamethasone.Approved
CabergolineThe serum concentration of Cabergoline can be decreased when it is combined with Dexamethasone.Approved
CabozantinibThe serum concentration of Cabozantinib can be decreased when it is combined with Dexamethasone.Approved
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Dexamethasone.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Dexamethasone.Approved, Nutraceutical
Calcium carbonateThe bioavailability of Dexamethasone can be decreased when combined with Calcium carbonate.Approved
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Dexamethasone.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Dexamethasone.Approved
CandesartanThe serum concentration of Dexamethasone can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Dexamethasone can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Dexamethasone can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbamazepineThe metabolism of Dexamethasone can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe serum concentration of Carbinoxamine can be decreased when it is combined with Dexamethasone.Approved
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Dexamethasone.Approved
CariprazineThe serum concentration of Cariprazine can be decreased when it is combined with Dexamethasone.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Dexamethasone.Approved, Vet Approved, Withdrawn
CarvedilolThe serum concentration of Carvedilol can be decreased when it is combined with Dexamethasone.Approved, Investigational
CaspofunginThe serum concentration of Caspofungin can be decreased when it is combined with Dexamethasone.Approved
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Dexamethasone.Experimental
CDX-110The risk or severity of adverse effects can be increased when Dexamethasone is combined with CDX-110.Investigational
CelecoxibThe serum concentration of Celecoxib can be decreased when it is combined with Dexamethasone.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Dexamethasone.Approved, Investigational
CephalexinThe serum concentration of Cephalexin can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
CeritinibThe serum concentration of Dexamethasone can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Dexamethasone.Withdrawn
CevimelineThe serum concentration of Cevimeline can be decreased when it is combined with Dexamethasone.Approved
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Dexamethasone.Approved
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be decreased when it is combined with Dexamethasone.Approved, Illicit
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
ChlorothiazideDexamethasone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Dexamethasone can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorphenamineThe serum concentration of Chlorphenamine can be decreased when it is combined with Dexamethasone.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
ChlorpropamideThe serum concentration of Dexamethasone can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Dexamethasone can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneDexamethasone may increase the hypokalemic activities of Chlorthalidone.Approved
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be decreased when it is combined with Dexamethasone.Approved
CholecalciferolThe serum concentration of Cholecalciferol can be decreased when it is combined with Dexamethasone.Approved, Nutraceutical
CholesterolThe serum concentration of Dexamethasone can be increased when it is combined with Cholesterol.Experimental
CholestyramineCholestyramine can cause a decrease in the absorption of Dexamethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cholic AcidThe serum concentration of Dexamethasone can be decreased when it is combined with Cholic Acid.Approved
CiclesonideThe serum concentration of Ciclesonide can be decreased when it is combined with Dexamethasone.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Dexamethasone.Experimental
CilazaprilThe serum concentration of Dexamethasone can be increased when it is combined with Cilazapril.Approved
CilostazolThe serum concentration of Cilostazol can be decreased when it is combined with Dexamethasone.Approved
CimetidineThe serum concentration of Cimetidine can be decreased when it is combined with Dexamethasone.Approved
CinacalcetThe serum concentration of Cinacalcet can be decreased when it is combined with Dexamethasone.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be decreased when it is combined with Dexamethasone.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Dexamethasone.Approved
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Dexamethasone.Approved
ClarithromycinThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Dexamethasone.Approved
ClemastineThe metabolism of Dexamethasone can be decreased when combined with Clemastine.Approved
ClindamycinThe serum concentration of Clindamycin can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Dexamethasone.Approved, Illicit
ClofazimineThe serum concentration of Clofazimine can be decreased when it is combined with Dexamethasone.Approved, Investigational
ClofibrateThe serum concentration of Clofibrate can be decreased when it is combined with Dexamethasone.Approved
clomethiazoleThe serum concentration of clomethiazole can be decreased when it is combined with Dexamethasone.Investigational
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Dexamethasone.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
ClonazepamThe serum concentration of Clonazepam can be decreased when it is combined with Dexamethasone.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Dexamethasone.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Dexamethasone.Approved
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Dexamethasone.Approved, Nutraceutical
ClorazepateThe serum concentration of Clorazepate can be decreased when it is combined with Dexamethasone.Approved, Illicit
ClotiazepamThe serum concentration of Clotiazepam can be decreased when it is combined with Dexamethasone.Approved, Illicit
ClotrimazoleThe metabolism of Dexamethasone can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Dexamethasone.Approved
CobicistatThe serum concentration of Cobicistat can be decreased when it is combined with Dexamethasone.Approved
CobicistatThe metabolism of Dexamethasone can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Dexamethasone.Approved
CocaineThe serum concentration of Cocaine can be decreased when it is combined with Dexamethasone.Approved, Illicit
CodeineThe serum concentration of Codeine can be decreased when it is combined with Dexamethasone.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Dexamethasone.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Dexamethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Dexamethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColforsinThe serum concentration of Dexamethasone can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Dexamethasone can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Dexamethasone can be increased when it is combined with Conjugated Equine Estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Dexamethasone.Approved
Cortisone acetateThe serum concentration of Cortisone acetate can be decreased when it is combined with Dexamethasone.Approved
CoumaphosThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Coumaphos.Vet Approved
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Dexamethasone.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Dexamethasone.Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Dexamethasone.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Dexamethasone.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
CytarabineThe serum concentration of Cytarabine can be decreased when it is combined with Dexamethasone.Approved, Investigational
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Dexamethasone.Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Dexamethasone.Approved
DabrafenibThe serum concentration of Dexamethasone can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Daclatasvir can be decreased when it is combined with Dexamethasone.Approved
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Dexamethasone.Approved
DantroleneThe serum concentration of Dantrolene can be decreased when it is combined with Dexamethasone.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Dexamethasone.Approved
DapsoneThe serum concentration of Dapsone can be decreased when it is combined with Dexamethasone.Approved, Investigational
DarifenacinThe serum concentration of Darifenacin can be decreased when it is combined with Dexamethasone.Approved, Investigational
DarunavirThe metabolism of Dexamethasone can be decreased when combined with Darunavir.Approved
DasabuvirThe serum concentration of Dasabuvir can be decreased when it is combined with Dexamethasone.Approved
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Dexamethasone.Approved, Investigational
DasatinibThe serum concentration of Dexamethasone can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Dexamethasone.Approved
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Dexamethasone.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Dexamethasone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Dexamethasone.Approved
DemecariumThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Demecarium.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Dexamethasone.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Dexamethasone.Investigational
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Dexamethasone.Investigational
DesipramineThe serum concentration of Dexamethasone can be increased when it is combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Dexamethasone.Approved
DesloratadineThe serum concentration of Dexamethasone can be increased when it is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe serum concentration of Desvenlafaxine can be decreased when it is combined with Dexamethasone.Approved
DextromethorphanThe serum concentration of Dextromethorphan can be decreased when it is combined with Dexamethasone.Approved
DextropropoxypheneThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Dexamethasone.Approved, Illicit, Withdrawn
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Dexamethasone.Approved, Illicit, Vet Approved
DichlorvosThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Dichlorvos.Vet Approved
DiclofenacThe serum concentration of Diclofenac can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
DienestrolThe serum concentration of Dexamethasone can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Dexamethasone can be increased when it is combined with Diethylstilbestrol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Dexamethasone.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Dexamethasone.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Dexamethasone.Approved
DihydrocodeineThe serum concentration of Dihydrocodeine can be decreased when it is combined with Dexamethasone.Approved, Illicit
DihydroergotamineThe serum concentration of Dihydroergotamine can be decreased when it is combined with Dexamethasone.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Dexamethasone.Illicit
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Dexamethasone.Approved
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Dexamethasone.Approved
DisopyramideThe serum concentration of Disopyramide can be decreased when it is combined with Dexamethasone.Approved
DisulfiramThe serum concentration of Disulfiram can be decreased when it is combined with Dexamethasone.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Dexamethasone.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be decreased when it is combined with Dexamethasone.Approved
DolasetronThe serum concentration of Dolasetron can be decreased when it is combined with Dexamethasone.Approved
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DonepezilThe serum concentration of Donepezil can be decreased when it is combined with Dexamethasone.Approved
DorzolamideThe serum concentration of Dorzolamide can be decreased when it is combined with Dexamethasone.Approved
DoxazosinThe serum concentration of Dexamethasone can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Doxepin can be decreased when it is combined with Dexamethasone.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Dexamethasone.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Dexamethasone.Approved, Investigational
DoxycyclineThe metabolism of Dexamethasone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be decreased when it is combined with Dexamethasone.Approved, Illicit
DronedaroneThe serum concentration of Dronedarone can be decreased when it is combined with Dexamethasone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Dexamethasone.Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Dexamethasone.Approved
DutasterideThe serum concentration of Dutasteride can be decreased when it is combined with Dexamethasone.Approved, Investigational
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Dexamethasone.Investigational
E6201The risk or severity of adverse effects can be increased when E6201 is combined with Dexamethasone.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with Dexamethasone.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Echothiophate.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Dexamethasone.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Edrophonium.Approved
EfavirenzThe serum concentration of Dexamethasone can be decreased when it is combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Dexamethasone can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Dexamethasone.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be decreased when it is combined with Dexamethasone.Approved
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Dexamethasone.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Dexamethasone.Approved
EnalaprilThe serum concentration of Enalapril can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
EnoxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Enzalutamide can be decreased when it is combined with Dexamethasone.Approved
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Dexamethasone.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Dexamethasone.Approved
EplerenoneThe serum concentration of Eplerenone can be decreased when it is combined with Dexamethasone.Approved
ErgocalciferolThe serum concentration of Ergocalciferol can be decreased when it is combined with Dexamethasone.Approved, Nutraceutical
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Dexamethasone.Approved
ErgonovineThe serum concentration of Ergonovine can be decreased when it is combined with Dexamethasone.Approved
ErgotamineThe serum concentration of Ergotamine can be decreased when it is combined with Dexamethasone.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Dexamethasone.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
EscitalopramThe serum concentration of Escitalopram can be decreased when it is combined with Dexamethasone.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Dexamethasone can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe serum concentration of Esomeprazole can be decreased when it is combined with Dexamethasone.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be decreased when it is combined with Dexamethasone.Approved, Illicit
EstradiolThe serum concentration of Dexamethasone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe serum concentration of Estradiol valerate/Dienogest can be decreased when it is combined with Dexamethasone.Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Dexamethasone.Approved
EstriolThe serum concentration of Dexamethasone can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Dexamethasone can be increased when it is combined with Estrone.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Dexamethasone.Approved
EszopicloneThe serum concentration of Eszopiclone can be decreased when it is combined with Dexamethasone.Approved
Etacrynic acidDexamethasone may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Dexamethasone.Approved, Investigational
EthanolThe serum concentration of Ethanol can be decreased when it is combined with Dexamethasone.Approved
Ethinyl EstradiolThe serum concentration of Dexamethasone can be increased when it is combined with Ethinyl Estradiol.Approved
EthosuximideThe serum concentration of Ethosuximide can be decreased when it is combined with Dexamethasone.Approved
EthylmorphineThe serum concentration of Ethylmorphine can be decreased when it is combined with Dexamethasone.Approved, Illicit
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Dexamethasone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Dexamethasone.Approved
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Dexamethasone.Approved, Investigational
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Dexamethasone.Approved
EtoricoxibThe serum concentration of Etoricoxib can be decreased when it is combined with Dexamethasone.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Dexamethasone.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Dexamethasone.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Dexamethasone.Approved
ExemestaneThe serum concentration of Exemestane can be decreased when it is combined with Dexamethasone.Approved, Investigational
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Dexamethasone.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Dexamethasone.Investigational
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Dexamethasone.Approved
FamciclovirThe serum concentration of Famciclovir can be decreased when it is combined with Dexamethasone.Approved
FelbamateThe serum concentration of Felbamate can be decreased when it is combined with Dexamethasone.Approved
FelodipineThe serum concentration of Felodipine can be decreased when it is combined with Dexamethasone.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Dexamethasone.Approved
FenofibrateThe serum concentration of Fenofibrate can be decreased when it is combined with Dexamethasone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Dexamethasone.Approved
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Dexamethasone.Approved, Illicit, Investigational, Vet Approved
FenthionThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Fenthion.Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Dexamethasone.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Dexamethasone.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Dexamethasone.Approved
FinasterideThe serum concentration of Finasteride can be decreased when it is combined with Dexamethasone.Approved
FingolimodDexamethasone may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Fleroxacin.Approved
FlibanserinThe serum concentration of Flibanserin can be decreased when it is combined with Dexamethasone.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Dexamethasone.Approved, Withdrawn
FluconazoleThe metabolism of Dexamethasone can be decreased when combined with Fluconazole.Approved
FlumequineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Flumequine.Withdrawn
FlunisolideThe serum concentration of Flunisolide can be decreased when it is combined with Dexamethasone.Approved, Investigational
FlunitrazepamThe serum concentration of Flunitrazepam can be decreased when it is combined with Dexamethasone.Approved, Illicit
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Dexamethasone.Vet Approved
FluorometholoneThe serum concentration of Fluorometholone can be decreased when it is combined with Dexamethasone.Approved
FluoxetineThe serum concentration of Fluoxetine can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
FluoxymesteroneDexamethasone may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlupentixolThe serum concentration of Dexamethasone can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Dexamethasone can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Flurazepam can be decreased when it is combined with Dexamethasone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Dexamethasone.Approved, Investigational
FlutamideThe serum concentration of Flutamide can be decreased when it is combined with Dexamethasone.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Dexamethasone.Approved
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be decreased when it is combined with Dexamethasone.Approved
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Dexamethasone.Approved
FluvoxamineThe metabolism of Dexamethasone can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Dexamethasone.Approved
FosaprepitantThe serum concentration of Dexamethasone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Dexamethasone can be decreased when it is combined with Fosphenytoin.Approved
FosphenytoinThe metabolism of Dexamethasone can be increased when combined with Fosphenytoin.Approved
FulvestrantThe serum concentration of Fulvestrant can be decreased when it is combined with Dexamethasone.Approved, Investigational
FurosemideDexamethasone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Dexamethasone can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Dexamethasone is combined with G17DT.Investigational
GalantamineThe serum concentration of Galantamine can be decreased when it is combined with Dexamethasone.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Gatifloxacin.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Dexamethasone.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Dexamethasone.Approved
GemfibrozilThe serum concentration of Gemfibrozil can be decreased when it is combined with Dexamethasone.Approved
GemifloxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Dexamethasone can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Dexamethasone is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Ginkgo biloba.Approved, Nutraceutical
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Dexamethasone.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Dexamethasone.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Dexamethasone.Approved
GlipizideThe serum concentration of Glipizide can be decreased when it is combined with Dexamethasone.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Dexamethasone.Approved
GlyburideThe serum concentration of Glyburide can be decreased when it is combined with Dexamethasone.Approved
GlycerolThe serum concentration of Dexamethasone can be increased when it is combined with Glycerol.Experimental
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Dexamethasone.Approved
Gramicidin DThe serum concentration of Dexamethasone can be increased when it is combined with Gramicidin D.Approved
GranisetronThe serum concentration of Granisetron can be decreased when it is combined with Dexamethasone.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Dexamethasone.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Grepafloxacin.Withdrawn
GuanfacineThe serum concentration of Guanfacine can be decreased when it is combined with Dexamethasone.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Dexamethasone.Investigational
HalofantrineThe serum concentration of Halofantrine can be decreased when it is combined with Dexamethasone.Approved
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Dexamethasone.Approved
HalothaneThe serum concentration of Halothane can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
HexestrolThe serum concentration of Dexamethasone can be increased when it is combined with Hexestrol.Withdrawn
HexobarbitalThe serum concentration of Hexobarbital can be decreased when it is combined with Dexamethasone.Approved
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Dexamethasone.Investigational
Histamine PhosphateThe serum concentration of Histamine Phosphate can be decreased when it is combined with Dexamethasone.Approved
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Dexamethasone.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dexamethasone.Approved, Investigational
HydrochlorothiazideDexamethasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Dexamethasone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
HydroflumethiazideDexamethasone may increase the hypokalemic activities of Hydroflumethiazide.Approved
HydromorphoneThe serum concentration of Hydromorphone can be decreased when it is combined with Dexamethasone.Approved, Illicit
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Dexamethasone.Approved
IbrutinibThe serum concentration of Ibrutinib can be decreased when it is combined with Dexamethasone.Approved
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Dexamethasone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Dexamethasone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Dexamethasone.Approved
IdelalisibThe serum concentration of Dexamethasone can be increased when it is combined with Idelalisib.Approved
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Dexamethasone resulting in a loss in efficacy.Approved
IloperidoneThe serum concentration of Iloperidone can be decreased when it is combined with Dexamethasone.Approved
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Dexamethasone.Approved
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Dexamethasone.Approved
ImiquimodThe serum concentration of Imiquimod can be decreased when it is combined with Dexamethasone.Approved, Investigational
IndacaterolIndacaterol may increase the hypokalemic activities of Dexamethasone.Approved
IndapamideDexamethasone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe metabolism of Dexamethasone can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Dexamethasone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Dexamethasone.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Dexamethasone is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Dexamethasone is combined with INGN 225.Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Dexamethasone.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Dexamethasone.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Dexamethasone.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Dexamethasone.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Dexamethasone.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Dexamethasone.Approved
Ipratropium bromideThe serum concentration of Ipratropium bromide can be decreased when it is combined with Dexamethasone.Approved
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Dexamethasone.Approved, Investigational
IsavuconazoniumThe serum concentration of Isavuconazonium can be decreased when it is combined with Dexamethasone.Approved, Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Dexamethasone.Approved
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Dexamethasone.Approved
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Dexamethasone.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Dexamethasone.Withdrawn
IsradipineThe serum concentration of Isradipine can be decreased when it is combined with Dexamethasone.Approved
ItraconazoleThe metabolism of Dexamethasone can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be decreased when it is combined with Dexamethasone.Approved
IvacaftorThe serum concentration of Dexamethasone can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be decreased when it is combined with Dexamethasone.Approved, Investigational
IxazomibThe serum concentration of Ixazomib can be decreased when it is combined with Dexamethasone.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Dexamethasone.Experimental
KetamineThe serum concentration of Ketamine can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Dexamethasone.Approved
KetobemidoneThe serum concentration of Ketobemidone can be decreased when it is combined with Dexamethasone.Approved
KetoconazoleThe metabolism of Dexamethasone can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Dexamethasone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Dexamethasone.Approved
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Dexamethasone.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Dexamethasone.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Dexamethasone.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be decreased when it is combined with Dexamethasone.Approved, Investigational
LaquinimodThe serum concentration of Laquinimod can be decreased when it is combined with Dexamethasone.Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Dexamethasone.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Leflunomide.Approved, Investigational
LenalidomideDexamethasone may increase the thrombogenic activities of Lenalidomide.Approved
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Dexamethasone.Approved
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Dexamethasone.Approved
LercanidipineThe serum concentration of Lercanidipine can be decreased when it is combined with Dexamethasone.Approved, Investigational
LetrozoleThe serum concentration of Letrozole can be decreased when it is combined with Dexamethasone.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Dexamethasone.Approved, Investigational
LevobupivacaineThe serum concentration of Levobupivacaine can be decreased when it is combined with Dexamethasone.Approved
LevocetirizineThe serum concentration of Levocetirizine can be decreased when it is combined with Dexamethasone.Approved
LevofloxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Dexamethasone.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Dexamethasone.Approved
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Dexamethasone.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Dexamethasone.Approved
LidocaineThe serum concentration of Lidocaine can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Dexamethasone.Approved
LiothyronineThe serum concentration of Dexamethasone can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Dexamethasone can be decreased when it is combined with Liotrix.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Dexamethasone.Approved
LisinoprilThe serum concentration of Dexamethasone can be increased when it is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Dexamethasone.Investigational
LisurideThe serum concentration of Lisuride can be decreased when it is combined with Dexamethasone.Approved
LomefloxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Lomefloxacin.Approved
LomitapideThe serum concentration of Lomitapide can be decreased when it is combined with Dexamethasone.Approved
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Dexamethasone.Approved
LopinavirThe metabolism of Dexamethasone can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Loratadine can be decreased when it is combined with Dexamethasone.Approved
LorcaserinThe serum concentration of Lorcaserin can be decreased when it is combined with Dexamethasone.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Dexamethasone.Approved
LosartanThe serum concentration of Losartan can be decreased when it is combined with Dexamethasone.Approved
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Dexamethasone.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Dexamethasone.Approved
LuliconazoleThe serum concentration of Dexamethasone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Dexamethasone can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Lumefantrine can be decreased when it is combined with Dexamethasone.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Dexamethasone.Approved, Investigational
LurasidoneThe serum concentration of Lurasidone can be decreased when it is combined with Dexamethasone.Approved
MacitentanThe serum concentration of Macitentan can be decreased when it is combined with Dexamethasone.Approved
MagaldrateThe bioavailability of Dexamethasone can be decreased when combined with Magaldrate.Withdrawn
Magnesium carbonateThe bioavailability of Dexamethasone can be decreased when combined with Magnesium carbonate.Approved
Magnesium hydroxideThe bioavailability of Dexamethasone can be decreased when combined with Magnesium hydroxide.Approved
Magnesium oxideThe bioavailability of Dexamethasone can be decreased when combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Dexamethasone.Approved
Magnesium TrisilicateThe bioavailability of Dexamethasone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Malathion.Approved, Investigational
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Dexamethasone.Approved, Investigational
MaprotilineThe serum concentration of Dexamethasone can be increased when it is combined with Maprotiline.Approved
MaravirocThe serum concentration of Maraviroc can be decreased when it is combined with Dexamethasone.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Dexamethasone.Approved
MebendazoleThe serum concentration of Mebendazole can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Dexamethasone.Approved, Vet Approved
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Dexamethasone.Approved, Investigational
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Dexamethasone.Approved
MefloquineThe serum concentration of Mefloquine can be decreased when it is combined with Dexamethasone.Approved
Megestrol acetateThe serum concentration of Dexamethasone can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeloxicamThe serum concentration of Meloxicam can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Memantine.Approved, Investigational
MeprobamateThe serum concentration of Dexamethasone can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Dexamethasone.Approved
MestranolThe serum concentration of Dexamethasone can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Dexamethasone.Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Dexamethasone.Approved
MethadoneThe serum concentration of Methadone can be decreased when it is combined with Dexamethasone.Approved
MethallenestrilThe serum concentration of Dexamethasone can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Methanesulfonyl Fluoride.Investigational
MethaqualoneThe serum concentration of Methaqualone can be decreased when it is combined with Dexamethasone.Illicit, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Dexamethasone.Approved
MethoxsalenThe serum concentration of Methoxsalen can be decreased when it is combined with Dexamethasone.Approved
MethoxyfluraneThe serum concentration of Methoxyflurane can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
MethyclothiazideDexamethasone may increase the hypokalemic activities of Methyclothiazide.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
MethyltestosteroneThe serum concentration of Methyltestosterone can be decreased when it is combined with Dexamethasone.Approved
MetolazoneDexamethasone may increase the hypokalemic activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Dexamethasone.Approved, Investigational
MetronidazoleThe serum concentration of Metronidazole can be decreased when it is combined with Dexamethasone.Approved
MexiletineThe serum concentration of Mexiletine can be decreased when it is combined with Dexamethasone.Approved
MianserinThe serum concentration of Mianserin can be decreased when it is combined with Dexamethasone.Approved
MibefradilThe serum concentration of Mibefradil can be decreased when it is combined with Dexamethasone.Withdrawn
MiconazoleThe serum concentration of Miconazole can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Dexamethasone.Approved, Illicit
MifepristoneThe therapeutic efficacy of Dexamethasone can be decreased when used in combination with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Dexamethasone.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Dexamethasone.Approved
MinaprineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Minaprine.Approved
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Dexamethasone.Approved
MirtazapineThe serum concentration of Mirtazapine can be decreased when it is combined with Dexamethasone.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Dexamethasone.Approved, Investigational
MitomycinThe serum concentration of Dexamethasone can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Dexamethasone can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Dexamethasone.Approved, Investigational
MivacuriumMivacurium may increase the adverse neuromuscular activities of Dexamethasone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Dexamethasone.Investigational
ModafinilThe serum concentration of Dexamethasone can be decreased when it is combined with Modafinil.Approved, Investigational
MontelukastThe serum concentration of Montelukast can be decreased when it is combined with Dexamethasone.Approved
MorphineThe serum concentration of Morphine can be decreased when it is combined with Dexamethasone.Approved, Investigational
MoxifloxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Dexamethasone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Dexamethasone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Dexamethasone.Approved
NadololThe serum concentration of Nadolol can be decreased when it is combined with Dexamethasone.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Dexamethasone.Investigational
NafcillinThe serum concentration of Dexamethasone can be decreased when it is combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Dexamethasone.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Nalidixic Acid.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Dexamethasone.Approved
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
NaltrexoneThe serum concentration of Dexamethasone can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Dexamethasone.Approved, Vet Approved
NaringeninThe serum concentration of Dexamethasone can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Natalizumab.Approved, Investigational
NateglinideThe serum concentration of Nateglinide can be decreased when it is combined with Dexamethasone.Approved, Investigational
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Dexamethasone.Investigational
NefazodoneThe metabolism of Dexamethasone can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Dexamethasone can be decreased when combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Nemonoxacin.Investigational
NeostigmineThe serum concentration of Dexamethasone can be increased when it is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Dexamethasone.Approved
NetupitantThe serum concentration of Dexamethasone can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Dexamethasone can be decreased when it is combined with Nevirapine.Approved
NevirapineThe metabolism of Dexamethasone can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Dexamethasone.Approved
NicorandilThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Nicorandil.Approved
NicotineThe serum concentration of Nicotine can be decreased when it is combined with Dexamethasone.Approved
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Dexamethasone.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Dexamethasone.Approved
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Dexamethasone.Approved, Investigational
NilvadipineThe serum concentration of Nilvadipine can be decreased when it is combined with Dexamethasone.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Dexamethasone.Approved, Withdrawn
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Dexamethasone.Approved
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Dexamethasone.Approved
NisoldipineThe serum concentration of Nisoldipine can be decreased when it is combined with Dexamethasone.Approved
NitrazepamThe serum concentration of Nitrazepam can be decreased when it is combined with Dexamethasone.Approved
NitrendipineThe serum concentration of Nitrendipine can be decreased when it is combined with Dexamethasone.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Dexamethasone.Investigational
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Dexamethasone.Approved
NorethisteroneThe serum concentration of Norethisterone can be decreased when it is combined with Dexamethasone.Approved
NorfloxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Norfloxacin.Approved
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Dexamethasone.Approved
NortriptylineThe serum concentration of Nortriptyline can be decreased when it is combined with Dexamethasone.Approved
OfloxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Ofloxacin.Approved
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Dexamethasone.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be decreased when it is combined with Dexamethasone.Approved
OlopatadineThe serum concentration of Olopatadine can be decreased when it is combined with Dexamethasone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Dexamethasone.Approved
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Dexamethasone.Approved
OmeprazoleThe serum concentration of Omeprazole can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of Ondansetron can be decreased when it is combined with Dexamethasone.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Dexamethasone.Vet Approved
OrphenadrineThe serum concentration of Orphenadrine can be decreased when it is combined with Dexamethasone.Approved
OsimertinibThe serum concentration of Dexamethasone can be increased when it is combined with Osimertinib.Approved
OspemifeneThe serum concentration of Ospemifene can be decreased when it is combined with Dexamethasone.Approved
OuabainOuabain may decrease the cardiotoxic activities of Dexamethasone.Approved
OxandroloneDexamethasone may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Dexamethasone.Approved
OxazepamThe serum concentration of Oxazepam can be decreased when it is combined with Dexamethasone.Approved
OxybutyninThe serum concentration of Oxybutynin can be decreased when it is combined with Dexamethasone.Approved, Investigational
OxycodoneThe serum concentration of Oxycodone can be decreased when it is combined with Dexamethasone.Approved, Illicit, Investigational
OxymetholoneDexamethasone may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxymorphoneThe serum concentration of Oxymorphone can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Dexamethasone.Withdrawn
P-NitrophenolThe serum concentration of Dexamethasone can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Dexamethasone.Approved, Vet Approved
PalbociclibThe serum concentration of Palbociclib can be decreased when it is combined with Dexamethasone.Approved
Palmitic AcidThe serum concentration of Dexamethasone can be increased when it is combined with Palmitic Acid.Experimental
PalonosetronThe serum concentration of Palonosetron can be decreased when it is combined with Dexamethasone.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Dexamethasone.Approved, Investigational
PantoprazoleThe serum concentration of Pantoprazole can be decreased when it is combined with Dexamethasone.Approved
ParamethadioneThe serum concentration of Paramethadione can be decreased when it is combined with Dexamethasone.Approved
ParamethasoneThe serum concentration of Paramethasone can be decreased when it is combined with Dexamethasone.Approved
ParecoxibThe serum concentration of Parecoxib can be decreased when it is combined with Dexamethasone.Approved
ParicalcitolThe serum concentration of Paricalcitol can be decreased when it is combined with Dexamethasone.Approved, Investigational
ParitaprevirThe serum concentration of Paritaprevir can be decreased when it is combined with Dexamethasone.Approved
ParoxetineThe serum concentration of Dexamethasone can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Dexamethasone.Approved
PazufloxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Pefloxacin.Approved
PentamidineThe serum concentration of Pentamidine can be decreased when it is combined with Dexamethasone.Approved
PentobarbitalThe serum concentration of Dexamethasone can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PentobarbitalThe metabolism of Dexamethasone can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelThe serum concentration of Perampanel can be decreased when it is combined with Dexamethasone.Approved
PergolideThe serum concentration of Pergolide can be decreased when it is combined with Dexamethasone.Approved, Vet Approved, Withdrawn
PerhexilineThe serum concentration of Perhexiline can be decreased when it is combined with Dexamethasone.Approved
PerindoprilThe serum concentration of Dexamethasone can be increased when it is combined with Perindopril.Approved
PermethrinThe serum concentration of Permethrin can be decreased when it is combined with Dexamethasone.Approved, Investigational
PerphenazineThe serum concentration of Perphenazine can be decreased when it is combined with Dexamethasone.Approved
PethidineThe serum concentration of Pethidine can be decreased when it is combined with Dexamethasone.Approved
PhenacetinThe serum concentration of Phenacetin can be decreased when it is combined with Dexamethasone.Withdrawn
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Dexamethasone.Approved, Withdrawn
PhenobarbitalThe serum concentration of Dexamethasone can be decreased when it is combined with Phenobarbital.Approved
PhenobarbitalThe metabolism of Dexamethasone can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe serum concentration of Phenoxybenzamine can be decreased when it is combined with Dexamethasone.Approved
PhenprocoumonThe serum concentration of Phenprocoumon can be decreased when it is combined with Dexamethasone.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Dexamethasone.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Dexamethasone.Approved, Vet Approved
PhenytoinThe serum concentration of Dexamethasone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhenytoinThe metabolism of Dexamethasone can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Physostigmine.Approved
PilocarpineThe serum concentration of Pilocarpine can be decreased when it is combined with Dexamethasone.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dexamethasone.Approved, Investigational
PimozideThe serum concentration of Pimozide can be decreased when it is combined with Dexamethasone.Approved
PinacidilThe serum concentration of Pinacidil can be decreased when it is combined with Dexamethasone.Withdrawn
PioglitazoneThe serum concentration of Pioglitazone can be decreased when it is combined with Dexamethasone.Approved, Investigational
PipotiazineThe serum concentration of Pipotiazine can be decreased when it is combined with Dexamethasone.Approved
PiretanideDexamethasone may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Dexamethasone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Dexamethasone.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Dexamethasone.Approved
Platelet Activating FactorThe serum concentration of Dexamethasone can be decreased when it is combined with Platelet Activating Factor.Experimental
PodofiloxThe serum concentration of Podofilox can be decreased when it is combined with Dexamethasone.Approved
Polyestradiol phosphateThe serum concentration of Dexamethasone can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideDexamethasone may increase the hypokalemic activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Dexamethasone.Approved
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Dexamethasone.Approved
PosaconazoleThe metabolism of Dexamethasone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Dexamethasone.Approved, Investigational
PrasteroneThe serum concentration of Prasterone can be decreased when it is combined with Dexamethasone.Approved, Nutraceutical
PrasugrelThe serum concentration of Prasugrel can be decreased when it is combined with Dexamethasone.Approved
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Dexamethasone.Approved
PrazepamThe serum concentration of Prazepam can be decreased when it is combined with Dexamethasone.Approved, Illicit
PraziquantelThe serum concentration of Praziquantel can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Dexamethasone.Approved
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
PrimaquineThe serum concentration of Primaquine can be decreased when it is combined with Dexamethasone.Approved
PrimidoneThe serum concentration of Dexamethasone can be decreased when it is combined with Primidone.Approved, Vet Approved
PrimidoneThe metabolism of Dexamethasone can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Dexamethasone can be increased when it is combined with Probenecid.Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
ProguanilThe serum concentration of Proguanil can be decreased when it is combined with Dexamethasone.Approved
PromazineThe serum concentration of Promazine can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
PromestrieneThe serum concentration of Dexamethasone can be increased when it is combined with Promestriene.Investigational
PromethazineThe serum concentration of Dexamethasone can be increased when it is combined with Promethazine.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Dexamethasone.Approved
PropafenoneThe serum concentration of Propafenone can be decreased when it is combined with Dexamethasone.Approved
PropofolThe serum concentration of Propofol can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Dexamethasone.Approved, Investigational
ProtriptylineThe serum concentration of Dexamethasone can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Dexamethasone.Approved
PrulifloxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Dexamethasone.Investigational
PyrazinamideThe serum concentration of Pyrazinamide can be decreased when it is combined with Dexamethasone.Approved
PyridostigmineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Pyridostigmine.Approved
QuazepamThe serum concentration of Quazepam can be decreased when it is combined with Dexamethasone.Approved, Illicit
QuercetinThe serum concentration of Dexamethasone can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Dexamethasone.Approved
QuinacrineThe serum concentration of Quinacrine can be decreased when it is combined with Dexamethasone.Approved
QuinestrolThe serum concentration of Dexamethasone can be increased when it is combined with Quinestrol.Approved
QuinethazoneDexamethasone may increase the hypokalemic activities of Quinethazone.Approved
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Dexamethasone.Approved
QuinineThe serum concentration of Quinine can be decreased when it is combined with Dexamethasone.Approved
RabeprazoleThe serum concentration of Rabeprazole can be decreased when it is combined with Dexamethasone.Approved, Investigational
Rabies vaccineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Rabies vaccine.Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Dexamethasone.Approved
RaloxifeneThe serum concentration of Raloxifene can be decreased when it is combined with Dexamethasone.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be decreased when it is combined with Dexamethasone.Approved, Investigational
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Dexamethasone.Approved
RanolazineThe serum concentration of Ranolazine can be decreased when it is combined with Dexamethasone.Approved, Investigational
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Dexamethasone.Withdrawn
ReboxetineThe serum concentration of Reboxetine can be decreased when it is combined with Dexamethasone.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be decreased when it is combined with Dexamethasone.Approved
RepaglinideThe serum concentration of Repaglinide can be decreased when it is combined with Dexamethasone.Approved, Investigational
ReserpineThe serum concentration of Dexamethasone can be decreased when it is combined with Reserpine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Dexamethasone.Experimental, Investigational
RetapamulinThe serum concentration of Retapamulin can be decreased when it is combined with Dexamethasone.Approved
RifabutinThe serum concentration of Dexamethasone can be decreased when it is combined with Rifabutin.Approved
RifabutinThe metabolism of Dexamethasone can be increased when combined with Rifabutin.Approved
RifampicinThe serum concentration of Dexamethasone can be decreased when it is combined with Rifampicin.Approved
RifampicinThe metabolism of Dexamethasone can be increased when combined with Rifampicin.Approved
RifapentineThe serum concentration of Dexamethasone can be decreased when it is combined with Rifapentine.Approved
RifapentineThe metabolism of Dexamethasone can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Dexamethasone.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Dexamethasone.Approved
RimonabantThe serum concentration of Rimonabant can be decreased when it is combined with Dexamethasone.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Dexamethasone.Approved
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Dexamethasone.Approved, Investigational
RitonavirThe metabolism of Dexamethasone can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Dexamethasone.Approved
RivastigmineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Rivastigmine.Approved, Investigational
RofecoxibThe serum concentration of Rofecoxib can be decreased when it is combined with Dexamethasone.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Dexamethasone.Approved
RolapitantThe serum concentration of Rolapitant can be decreased when it is combined with Dexamethasone.Approved
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Dexamethasone.Approved, Investigational
RopiniroleThe serum concentration of Ropinirole can be decreased when it is combined with Dexamethasone.Approved, Investigational
RopivacaineThe serum concentration of Ropivacaine can be decreased when it is combined with Dexamethasone.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Dexamethasone.Approved, Investigational
RosoxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Rosoxacin.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Dexamethasone.Approved
RotigotineThe serum concentration of Rotigotine can be decreased when it is combined with Dexamethasone.Approved
RoxithromycinThe serum concentration of Roxithromycin can be decreased when it is combined with Dexamethasone.Approved, Withdrawn
RuxolitinibThe serum concentration of Ruxolitinib can be decreased when it is combined with Dexamethasone.Approved
S EquolThe serum concentration of Dexamethasone can be increased when it is combined with S Equol.Investigational
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Dexamethasone.Approved
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be decreased when it is combined with Dexamethasone.Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Dexamethasone.Approved
SaquinavirThe metabolism of Dexamethasone can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Dexamethasone.Approved
ScopolamineThe serum concentration of Dexamethasone can be increased when it is combined with Scopolamine.Approved
SecoisolariciresinolThe serum concentration of Dexamethasone can be increased when it is combined with Secoisolariciresinol.Investigational
SelegilineThe serum concentration of Selegiline can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Dexamethasone.Approved
SeratrodastThe serum concentration of Seratrodast can be decreased when it is combined with Dexamethasone.Approved, Investigational
SertindoleThe serum concentration of Sertindole can be decreased when it is combined with Dexamethasone.Approved, Withdrawn
SertralineThe serum concentration of Sertraline can be decreased when it is combined with Dexamethasone.Approved
SevofluraneThe serum concentration of Sevoflurane can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
SibutramineThe serum concentration of Sibutramine can be decreased when it is combined with Dexamethasone.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Sildenafil can be decreased when it is combined with Dexamethasone.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Dexamethasone.Approved
SiltuximabThe serum concentration of Dexamethasone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Dexamethasone.Approved
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Dexamethasone.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Dexamethasone.Approved
SirolimusThe serum concentration of Sirolimus can be decreased when it is combined with Dexamethasone.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Dexamethasone.Approved, Investigational
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Dexamethasone.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Dexamethasone.Approved
SolifenacinThe serum concentration of Solifenacin can be decreased when it is combined with Dexamethasone.Approved
SonidegibThe serum concentration of Sonidegib can be decreased when it is combined with Dexamethasone.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Dexamethasone.Approved, Investigational
SparfloxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Sparfloxacin.Approved
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Dexamethasone.Experimental
SpiramycinThe serum concentration of Spiramycin can be decreased when it is combined with Dexamethasone.Approved
SpironolactoneThe serum concentration of Dexamethasone can be increased when it is combined with Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Dexamethasone is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Dexamethasone.Investigational
St. John's WortThe serum concentration of Dexamethasone can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololDexamethasone may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StaurosporineThe serum concentration of Dexamethasone can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Dexamethasone can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Dexamethasone can be decreased when it is combined with Streptozocin.Approved
SufentanilThe serum concentration of Sufentanil can be decreased when it is combined with Dexamethasone.Approved, Investigational
SulfadiazineThe serum concentration of Sulfadiazine can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
SulfamethoxazoleThe serum concentration of Sulfamethoxazole can be decreased when it is combined with Dexamethasone.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Dexamethasone.Approved
SulfinpyrazoneThe serum concentration of Sulfinpyrazone can be decreased when it is combined with Dexamethasone.Approved
SulfisoxazoleThe metabolism of Dexamethasone can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Dexamethasone.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Dexamethasone.Approved, Investigational
SumatriptanThe serum concentration of Dexamethasone can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Sunitinib can be decreased when it is combined with Dexamethasone.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Dexamethasone.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Dexamethasone can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Dexamethasone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe serum concentration of Dexamethasone can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Dexamethasone.Approved, Investigational
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Dexamethasone.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be decreased when it is combined with Dexamethasone.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Dexamethasone.Approved
TamsulosinThe serum concentration of Tamsulosin can be decreased when it is combined with Dexamethasone.Approved, Investigational
TasosartanThe serum concentration of Tasosartan can be decreased when it is combined with Dexamethasone.Approved
Taurochenodeoxycholic acidThe serum concentration of Taurochenodeoxycholic acid can be decreased when it is combined with Dexamethasone.Experimental
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Dexamethasone.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Dexamethasone.Approved
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Dexamethasone.Approved
TelithromycinThe metabolism of Dexamethasone can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Dexamethasone can be increased when it is combined with Telmisartan.Approved, Investigational
TemafloxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Temafloxacin.Withdrawn
TemazepamThe serum concentration of Temazepam can be decreased when it is combined with Dexamethasone.Approved
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Dexamethasone.Approved
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Dexamethasone.Approved
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Dexamethasone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Dexamethasone.Vet Approved
TerazosinThe serum concentration of Dexamethasone can be increased when it is combined with Terazosin.Approved
TerbinafineThe serum concentration of Terbinafine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Terfenadine can be decreased when it is combined with Dexamethasone.Withdrawn
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Dexamethasone.Approved
TesmilifeneThe serum concentration of Tesmilifene can be decreased when it is combined with Dexamethasone.Investigational
TestosteroneThe serum concentration of Testosterone can be decreased when it is combined with Dexamethasone.Approved, Investigational
TetracyclineThe serum concentration of Tetracycline can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
TG4010The risk or severity of adverse effects can be increased when Dexamethasone is combined with TG4010.Investigational
ThalidomideDexamethasone may increase the dermatologic adverse activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Dexamethasone.Approved
ThiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Dexamethasone.Investigational
ThiotepaThe serum concentration of Thiotepa can be decreased when it is combined with Dexamethasone.Approved
TiagabineThe serum concentration of Tiagabine can be decreased when it is combined with Dexamethasone.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Dexamethasone.Approved
TiboloneThe serum concentration of Dexamethasone can be increased when it is combined with Tibolone.Approved
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Dexamethasone resulting in a loss in efficacy.Approved
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Dexamethasone.Approved
TiclopidineThe serum concentration of Ticlopidine can be decreased when it is combined with Dexamethasone.Approved
TimololThe serum concentration of Timolol can be decreased when it is combined with Dexamethasone.Approved
TinidazoleThe serum concentration of Tinidazole can be decreased when it is combined with Dexamethasone.Approved, Investigational
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Dexamethasone.Investigational
TiotropiumThe serum concentration of Tiotropium can be decreased when it is combined with Dexamethasone.Approved
TipranavirThe serum concentration of Tipranavir can be decreased when it is combined with Dexamethasone.Approved, Investigational
TocilizumabThe serum concentration of Dexamethasone can be decreased when it is combined with Tocilizumab.Approved
TofacitinibDexamethasone may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Dexamethasone.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Dexamethasone.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Dexamethasone.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Dexamethasone.Approved
TolterodineThe serum concentration of Tolterodine can be decreased when it is combined with Dexamethasone.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Dexamethasone.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Dexamethasone.Approved, Investigational
TorasemideDexamethasone may increase the hypokalemic activities of Torasemide.Approved
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Dexamethasone.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be decreased when it is combined with Dexamethasone.Approved, Investigational
TramadolThe serum concentration of Tramadol can be decreased when it is combined with Dexamethasone.Approved, Investigational
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Dexamethasone.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Dexamethasone.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Dexamethasone.Approved
TrazodoneThe serum concentration of Trazodone can be decreased when it is combined with Dexamethasone.Approved, Investigational
TretinoinThe serum concentration of Tretinoin can be decreased when it is combined with Dexamethasone.Approved, Investigational, Nutraceutical
TriamcinoloneThe serum concentration of Triamcinolone can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
TriazolamThe serum concentration of Triazolam can be decreased when it is combined with Dexamethasone.Approved
TrichlorfonThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Trichlorfon.Vet Approved
TrichlormethiazideDexamethasone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe serum concentration of Dexamethasone can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Dexamethasone can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethadioneThe serum concentration of Trimethadione can be decreased when it is combined with Dexamethasone.Approved
TrimethoprimThe serum concentration of Trimethoprim can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be decreased when it is combined with Dexamethasone.Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Dexamethasone.Approved
TroglitazoneThe serum concentration of Troglitazone can be decreased when it is combined with Dexamethasone.Withdrawn
TroleandomycinThe serum concentration of Troleandomycin can be decreased when it is combined with Dexamethasone.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Tubocurarine.Approved
UdenafilThe serum concentration of Udenafil can be decreased when it is combined with Dexamethasone.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Dexamethasone.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Dexamethasone.Approved
ValdecoxibThe serum concentration of Valdecoxib can be decreased when it is combined with Dexamethasone.Investigational, Withdrawn
VandetanibThe serum concentration of Vandetanib can be decreased when it is combined with Dexamethasone.Approved
VanoxerineThe serum concentration of Vanoxerine can be decreased when it is combined with Dexamethasone.Investigational
VardenafilThe serum concentration of Vardenafil can be decreased when it is combined with Dexamethasone.Approved
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Dexamethasone.Approved
VemurafenibThe serum concentration of Vemurafenib can be decreased when it is combined with Dexamethasone.Approved
VenetoclaxThe serum concentration of Venetoclax can be decreased when it is combined with Dexamethasone.Approved
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Dexamethasone.Approved
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Dexamethasone.Approved
VicrivirocThe serum concentration of Vicriviroc can be decreased when it is combined with Dexamethasone.Investigational
VilanterolThe serum concentration of Vilanterol can be decreased when it is combined with Dexamethasone.Approved
VilazodoneThe serum concentration of Vilazodone can be decreased when it is combined with Dexamethasone.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Dexamethasone.Approved, Investigational
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Dexamethasone.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Dexamethasone.Approved, Investigational
VindesineThe serum concentration of Vindesine can be decreased when it is combined with Dexamethasone.Approved
VinorelbineThe serum concentration of Vinorelbine can be decreased when it is combined with Dexamethasone.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Dexamethasone.Approved
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Dexamethasone.Approved, Investigational
VoriconazoleThe metabolism of Dexamethasone can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be decreased when it is combined with Dexamethasone.Approved
WarfarinDexamethasone may increase the anticoagulant activities of Warfarin.Approved
YohimbineThe serum concentration of Yohimbine can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
ZafirlukastThe serum concentration of Zafirlukast can be decreased when it is combined with Dexamethasone.Approved, Investigational
ZalcitabineThe serum concentration of Zalcitabine can be decreased when it is combined with Dexamethasone.Approved
ZaleplonThe serum concentration of Zaleplon can be decreased when it is combined with Dexamethasone.Approved, Illicit, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Dexamethasone.Approved
ZeranolThe serum concentration of Dexamethasone can be increased when it is combined with Zeranol.Vet Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Dexamethasone.Approved
ZileutonThe serum concentration of Zileuton can be decreased when it is combined with Dexamethasone.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Dexamethasone can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe serum concentration of Ziprasidone can be decreased when it is combined with Dexamethasone.Approved
ZolpidemThe serum concentration of Zolpidem can be decreased when it is combined with Dexamethasone.Approved
ZomepiracThe serum concentration of Zomepirac can be decreased when it is combined with Dexamethasone.Withdrawn
ZonisamideThe serum concentration of Zonisamide can be decreased when it is combined with Dexamethasone.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be decreased when it is combined with Dexamethasone.Approved
Food Interactions
  • Avoid alcohol.
  • Avoid taking with grapefruit juice.
  • Take with food to reduce irritation.
References
Synthesis Reference

Fried, J.; US. Patent 2,852.51 1; September 16, 1958; assigned to Olin Mathieson Chemical Corporation.
Muller, G., Bardoneschi, R. and Jolly, J.; U.S. Patent 3,007,923; November 7, 1961; assigned to Les Laboratories Francais de Chimiotherapie, France.

General ReferencesNot Available
External Links
ATC CodesS03CA01R01AD03S02CA06H02AB02C05AA09S01BA01S01CB01A01AC02D10AA03S02BA06D07AB19D07XB05D07CB04R01AD53S01CA01S03BA01
AHFS Codes
  • 52:08.08
  • 68:04.00
PDB EntriesNot Available
FDA labelDownload (96 KB)
MSDSDownload (74.8 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.992
Blood Brain Barrier+0.9781
Caco-2 permeable+0.8304
P-glycoprotein substrateSubstrate0.7862
P-glycoprotein inhibitor INon-inhibitor0.8112
P-glycoprotein inhibitor IINon-inhibitor0.8134
Renal organic cation transporterNon-inhibitor0.7971
CYP450 2C9 substrateNon-substrate0.8733
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.7315
CYP450 1A2 substrateNon-inhibitor0.938
CYP450 2C9 inhibitorNon-inhibitor0.9106
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9247
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9169
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9399
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.1482 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9558
hERG inhibition (predictor II)Inhibitor0.5091
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
ImplantIntracardiac.7 mg
SuspensionAuricular (otic)
Suspension / dropsAuricular (otic)
LiquidDental
LiquidAuricular (otic); Ophthalmic1 mg
TabletOral.5 mg
ElixirOral.5 mg/5mL
SolutionOral.5 mg/5mL
TabletOral.5 mg/1
TabletOral.75 mg/1
TabletOral1 mg/1
TabletOral1.5 mg/1
TabletOral2 mg/1
TabletOral4 mg/1
TabletOral6 mg/1
Solution, concentrateOral1 mg/mL
SolutionIntramuscular; Intrasynovial; Intravenous10 mg
LiquidIntramuscular; Intrasynovial; Intravenous10 mg
InjectionIntra-articular; Intralesional; Intramuscular; Intravenous4 mg/5mL
InjectionIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue4 mg/mL
InjectionIntramuscular10 mg/mL
InjectionIntramuscular; Intravenous10 mg/mL
Injection, solutionIntra-articular4 mg/mL
Injection, solutionIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue4 mg/mL
Injection, solutionIntra-articular; Intramuscular; Intravenous4 mg/mL
Injection, solutionIntramuscular4 mg/mL
Injection, solutionIntramuscular; Intravenous10 mg/mL
Injection, solutionIntramuscular; Intravenous4 mg/mL
Injection, solutionIntravenous4 mg/mL
SolutionOphthalmic1 mg/mL
Solution / dropsOphthalmic1 mg/mL
SolutionIntramuscular; Intrasynovial; Intravenous4 mg
LiquidIntra-articular; Intramuscular; Intravenous4 mg
SolutionIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue4 mg
SolutionIntramuscular; Intravenous10 mg
LiquidIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue4 mg
SolutionAuricular (otic); Ophthalmic0.1 %
OintmentOphthalmic; Topical
ImplantIntracardiac.5 mg
ImplantIntracardiac0.5 mg
LiquidIntramuscular; Intravenous4 mg
SuspensionOphthalmic1 mg/mL
OintmentOphthalmic0.1 %
Solution / dropsOphthalmic0.1 %
OintmentOphthalmic
SuspensionOphthalmic
Solution / dropsOphthalmic
Suspension / dropsOphthalmic
LiquidAuricular (otic); Ophthalmic
TabletOral40 mg
LiquidOphthalmic; Topical.1 %
ImplantIntravitreal.7 mg/1
ImplantIntravitreal0.7 mg
ImplantIntravitreal700 micro
ElixirOral0.5 mg
LiquidOral0.5 mg
TabletOral0.5 mg
TabletOral0.75 mg
TabletOral4 mg
TabletOral2 mg
LiquidIntramuscular; Intravenous10 mg
SolutionIntra-articular; Intramuscular; Intravenous4 mg
Solution / dropsAuricular (otic); Ophthalmic.1 %
Solution / dropsAuricular (otic); Ophthalmic1 mg
SolutionAuricular (otic); Ophthalmic
OintmentAuricular (otic); Ophthalmic
Solution / dropsAuricular (otic); Ophthalmic
Solution / dropsTopical
OintmentTopical
Prices
Unit descriptionCostUnit
Ozurdex 0.7 mg implant1554.0USD implant
Maxidex 0.1% Suspension 15ml Bottle97.96USD bottle
Maxitrol 0.1-5-10000 Ointment 3.5 gm Tube87.3USD tube
Maxitrol 5-10000-0.1 Suspension 5ml Bottle75.88USD bottle
Maxidex 0.1% Suspension 5ml Bottle53.57USD bottle
Dexamethasone Sodium Phosphate 4 mg/ml Solution (1 Box = 25x1ml Vials)41.99USD box
Dexamethasone micronized powd41.31USD g
Dexamethasone powder21.27USD g
Dexamethasone Sodium Phosphate 0.1% Solution 5ml Bottle19.99USD bottle
Dexamethasone acetate powd15.12USD g
Dexamethasone sod ph powder14.24USD g
Dexamethasone Sodium Phosphate 4 mg/ml Solution 5ml Vial13.99USD vial
Dexamethasone Sodium Phosphate 10 mg/ml4.78USD ml
Dexamethasone Sodium Phosphate 4 mg/ml 1 Vial = 5ml4.0USD ml
Dexamethasone 0.1% eye drop3.43USD ml
Dexasol 0.1% eye drops3.38USD ml
Maxidex 0.1 % Ointment2.69USD g
Dexamethasone 10 mg/ml vial2.56USD ml
Maxidex 0.1% eye drops2.36USD ml
Dexamethasone Sodium Phosphate 4 mg/ml1.77USD ml
Maxidex 0.1 % Suspension1.73USD ml
Sandoz Dexamethasone Sod. Phosphate 0.1 % Solution1.38USD ml
Pms-Dexamethasone Sodium Phosp 10 mg/ml1.34USD ml
Dexamethasone 4 mg/ml vial1.04USD ml
Dexamethasone 6 mg tablet1.01USD tablet
Dexasone 4 mg Tablet0.86USD tablet
Apo-Dexamethasone 4 mg Tablet0.8USD tablet
Pms-Dexamethasone 4 mg Tablet0.8USD tablet
Ratio-Dexamethasone 4 mg Tablet0.8USD tablet
Dexamethasone 2 mg tablet0.68USD tablet
Dexamethasone 1 mg/1 ml soln0.65USD ml
Dexamethasone 4 mg tablet0.6USD tablet
Dexamethasone 1 mg tablet0.49USD tablet
Pms-Dexamethasone 0.75 mg Tablet0.47USD tablet
Pms-Dexamethasone 2 mg Tablet0.43USD tablet
Dexamethasone 0.5 mg/5ml Elixir0.4USD ml
Dexamethasone 0.75 mg tablet0.38USD tablet
Dexamethasone 1.5 mg tablet0.35USD tablet
Dexamethasone 0.5 mg tablet0.31USD tablet
Apo-Dexamethasone 0.5 mg Tablet0.21USD tablet
Pms-Dexamethasone 0.5 mg Tablet0.2USD tablet
Ratio-Dexamethasone 0.5 mg Tablet0.18USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6284804 No2000-08-102020-08-10Us
US6359016 No2000-08-102020-08-10Us
US6726918 No2000-10-202020-10-20Us
US6899717 No2003-11-012023-11-01Us
US7033605 No2000-10-202020-10-20Us
US7767223 No2001-11-282021-11-28Us
US7795316 No2008-08-032028-08-03Us
US8034366 No2003-01-092023-01-09Us
US8034370 No2003-01-092023-01-09Us
US8043628 No2000-10-202020-10-20Us
US8063031 No2000-10-202020-10-20Us
US8088407 No2000-10-202020-10-20Us
US8101582 No2007-12-192027-12-19Us
US8450287 No2007-12-192027-12-19Us
US8506987 No2003-01-092023-01-09Us
US8846650 No2005-06-042025-06-04Us
US9012437 No2000-10-202020-10-20Us
US9149486 No2002-09-132022-09-13Us
US9192511 No2003-01-092023-01-09Us
US9283178 No2000-10-202020-10-20Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point170-229Fried, J.; US. Patent 2,852.51 1; September 16, 1958; assigned to Olin Mathieson Chemical Corporation. Muller, G., Bardoneschi, R. and Jolly, J.; U.S. Patent 3,007,923; November 7, 1961; assigned to Les Laboratories Francais de Chimiotherapie, France.
water solubility89 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.83HANSCH,C ET AL. (1995)
logS-3.64ADME Research, USCD
Caco2 permeability-4.75ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0505 mg/mLALOGPS
logP1.93ALOGPS
logP1.68ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)12.42ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area94.83 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity102.49 m3·mol-1ChemAxon
Polarizability40.83 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassHydroxysteroids
Direct Parent21-hydroxysteroids
Alternative Parents
Substituents
  • 21-hydroxysteroid
  • Progestogin-skeleton
  • Pregnane-skeleton
  • 20-oxosteroid
  • 17-hydroxysteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • Halo-steroid
  • 9-halo-steroid
  • 3-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • Delta-1,4-steroid
  • Tertiary alcohol
  • Cyclic alcohol
  • Alpha-hydroxy ketone
  • Cyclic ketone
  • Secondary alcohol
  • Ketone
  • Halohydrin
  • Fluorohydrin
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl fluoride
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Warne JP, John CD, Christian HC, Morris JF, Flower RJ, Sugden D, Solito E, Gillies GE, Buckingham JC: Gene deletion reveals roles for annexin A1 in the regulation of lipolysis and IL-6 release in epididymal adipose tissue. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1264-73. Epub 2006 Jul 11. [PubMed:16835395 ]
  2. Grossman R, Yehuda R, Golier J, McEwen B, Harvey P, Maria NS: Cognitive effects of intravenous hydrocortisone in subjects with PTSD and healthy control subjects. Ann N Y Acad Sci. 2006 Jul;1071:410-21. [PubMed:16891588 ]
  3. Funato H, Kobayashi A, Watanabe Y: Differential effects of antidepressants on dexamethasone-induced nuclear translocation and expression of glucocorticoid receptor. Brain Res. 2006 Oct 30;1117(1):125-34. Epub 2006 Sep 7. [PubMed:16956592 ]
  4. Vaitkuviene A, Ulinskaite A, Meskys R, Duburs G, Klusa V, Liutkevicius E: Study of the interaction of 1,4-dihydropyridine derivatives with glucocorticoid hormone receptors from the rat liver. Pharmacol Rep. 2006 Jul-Aug;58(4):551-8. [PubMed:16963802 ]
  5. Wang D, Zhang H, Lang F, Yun CC: Acute activation of NHE3 by dexamethasone correlates with activation of SGK1 and requires a functional glucocorticoid receptor. Am J Physiol Cell Physiol. 2007 Jan;292(1):C396-404. Epub 2006 Sep 13. [PubMed:16971495 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
stimulator
General Function:
Transcription factor binding
Specific Function:
Orphan nuclear receptor. Component of a cascade required for the development of the hypothalamic-pituitary-adrenal-gonadal axis. Acts as a coregulatory protein that inhibits the transcriptional activity of other nuclear receptors through heterodimeric interactions. May also have a role in the development of the embryo and in the maintenance of embryonic stem cell pluripotency (By similarity).
Gene Name:
NR0B1
Uniprot ID:
P51843
Molecular Weight:
51717.185 Da
References
  1. Gummow BM, Scheys JO, Cancelli VR, Hammer GD: Reciprocal regulation of a glucocorticoid receptor-steroidogenic factor-1 transcription complex on the Dax-1 promoter by glucocorticoids and adrenocorticotropic hormone in the adrenal cortex. Mol Endocrinol. 2006 Nov;20(11):2711-23. Epub 2006 Jul 20. [PubMed:16857744 ]
  2. Yu CC, Li PH: In vivo inhibition of steroidogenic acute regulatory protein expression by dexamethasone parallels induction of the negative transcription factor DAX-1. Endocrine. 2006 Dec;30(3):313-23. [PubMed:17526944 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Structural molecule activity
Specific Function:
Plays important roles in the innate immune response as effector of glucocorticoid-mediated responses and regulator of the inflammatory process. Has anti-inflammatory activity (PubMed:8425544). Plays a role in glucocorticoid-mediated down-regulation of the early phase of the inflammatory response (By similarity). Promotes resolution of inflammation and wound healing (PubMed:25664854). Functions ...
Gene Name:
ANXA1
Uniprot ID:
P04083
Molecular Weight:
38713.855 Da
References
  1. Morand EF, Hall P, Hutchinson P, Yang YH: Regulation of annexin I in rheumatoid synovial cells by glucocorticoids and interleukin-1. Mediators Inflamm. 2006;2006(2):73835. [PubMed:16883066 ]
  2. John CD, Theogaraj E, Christian HC, Morris JF, Smith SF, Buckingham JC: Time-specific effects of perinatal glucocorticoid treatment on anterior pituitary morphology, annexin 1 expression and adrenocorticotrophic hormone secretion in the adult female rat. J Neuroendocrinol. 2006 Dec;18(12):949-59. [PubMed:17076770 ]
  3. Davies E, Omer S, Buckingham JC, Morris JF, Christian HC: Expression and externalization of annexin 1 in the adrenal gland: structure and function of the adrenal gland in annexin 1-null mutant mice. Endocrinology. 2007 Mar;148(3):1030-8. Epub 2006 Dec 7. [PubMed:17158208 ]
  4. Wang C, Wang J, Guo HF, Liu RY: Involvement of annexin I in the dexamethasone-mediated upregulation of A549 cells phagocytosis of apoptotic eosinophils. Immunol Lett. 2007 Aug 15;111(2):103-10. Epub 2007 Jul 2. [PubMed:17644190 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
negative modulator
General Function:
Tetrahydrobiopterin binding
Specific Function:
Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In macrophages, NO mediates tumoricidal and bactericidal actions. Also has nitrosylase activity and mediates cysteine S-nitrosylation of cytoplasmic target proteins such COX2. As component of the iNOS-S100A8/9 transnitrosylase complex involved in the selective inflammatory stimulus-dependent S-n...
Gene Name:
NOS2
Uniprot ID:
P35228
Molecular Weight:
131116.3 Da
References
  1. Soderberg M, Raffalli-Mathieu F, Lang MA: Regulation of the murine inducible nitric oxide synthase gene by dexamethasone involves a heterogeneous nuclear ribonucleoprotein I (hnRNPI) dependent pathway. Mol Immunol. 2007 May;44(12):3204-10. Epub 2007 Mar 26. [PubMed:17379310 ]
  2. Huang H, Lavoie-Lamoureux A, Moran K, Lavoie JP: IL-4 stimulates the expression of CXCL-8, E-selectin, VEGF, and inducible nitric oxide synthase mRNA by equine pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2007 May;292(5):L1147-54. [PubMed:17494951 ]
  3. Nandi J, Saud B, Zinkievich JM, Palma DT, Levine RA: 5-aminosalicylic acid improves indomethacin-induced enteropathy by inhibiting iNOS transcription in rats. Dig Dis Sci. 2008 Jan;53(1):123-32. Epub 2007 May 15. [PubMed:17503181 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. [PubMed:10490933 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, nad(p)h as one donor, and incorporation of one atom of oxygen
Specific Function:
Catalyzes the side-chain cleavage reaction of cholesterol to pregnenolone.
Gene Name:
CYP11A1
Uniprot ID:
P05108
Molecular Weight:
60101.87 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid 17-alpha-monooxygenase activity
Specific Function:
Conversion of pregnenolone and progesterone to their 17-alpha-hydroxylated products and subsequently to dehydroepiandrosterone (DHEA) and androstenedione. Catalyzes both the 17-alpha-hydroxylation and the 17,20-lyase reaction. Involved in sexual development during fetal life and at puberty.
Gene Name:
CYP17A1
Uniprot ID:
P05093
Molecular Weight:
57369.995 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxygen binding
Specific Function:
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name:
CYP19A1
Uniprot ID:
P11511
Molecular Weight:
57882.48 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Molecular Weight:
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Monooxygenase activity
Specific Function:
Exhibits low testosterone 6-beta-hydroxylase activity.
Gene Name:
CYP3A43
Uniprot ID:
Q9HB55
Molecular Weight:
57669.21 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Leukotriene-b4 20-monooxygenase activity
Specific Function:
Catalyzes the omega- and (omega-1)-hydroxylation of various fatty acids such as laurate, myristate and palmitate. Has little activity toward prostaglandins A1 and E1. Oxidizes arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE).
Gene Name:
CYP4A11
Uniprot ID:
Q02928
Molecular Weight:
59347.31 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Transporter activity
Specific Function:
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name:
ABCB11
Uniprot ID:
O95342
Molecular Weight:
146405.83 Da
References
  1. Fardel O, Payen L, Courtois A, Vernhet L, Lecureur V: Regulation of biliary drug efflux pump expression by hormones and xenobiotics. Toxicology. 2001 Oct 5;167(1):37-46. [PubMed:11557128 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Geick A, Eichelbaum M, Burk O: Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001 May 4;276(18):14581-7. Epub 2001 Jan 31. [PubMed:11297522 ]
  2. Romiti N, Tramonti G, Chieli E: Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol. 2002 Sep 1;183(2):83-91. [PubMed:12387747 ]
  3. Schuetz JD, Silverman JA, Thottassery JV, Furuya KN, Schuetz EG: Divergent regulation of the class II P-glycoprotein gene in primary cultures of hepatocytes versus H35 hepatoma by glucocorticoids. Cell Growth Differ. 1995 Oct;6(10):1321-32. [PubMed:8845310 ]
  4. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
  5. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389 ]
  6. Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. [PubMed:11785684 ]
  7. Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803. [PubMed:14661924 ]
  8. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P: Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest. 1995 Oct;96(4):1698-705. [PubMed:7560060 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Demeule M, Jodoin J, Beaulieu E, Brossard M, Beliveau R: Dexamethasone modulation of multidrug transporters in normal tissues. FEBS Lett. 1999 Jan 15;442(2-3):208-14. [PubMed:9929003 ]
  2. Schrenk D, Baus PR, Ermel N, Klein C, Vorderstemann B, Kauffmann HM: Up-regulation of transporters of the MRP family by drugs and toxins. Toxicol Lett. 2001 Mar 31;120(1-3):51-7. [PubMed:11323161 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Kullak-Ublick GA, Fisch T, Oswald M, Hagenbuch B, Meier PJ, Beuers U, Paumgartner G: Dehydroepiandrosterone sulfate (DHEAS): identification of a carrier protein in human liver and brain. FEBS Lett. 1998 Mar 13;424(3):173-6. [PubMed:9539145 ]
  2. Bossuyt X, Muller M, Hagenbuch B, Meier PJ: Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther. 1996 Mar;276(3):891-6. [PubMed:8786566 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Elahian F, Kalalinia F, Behravan J: Evaluation of indomethacin and dexamethasone effects on BCRP-mediated drug resistance in MCF-7 parental and resistant cell lines. Drug Chem Toxicol. 2010 Apr;33(2):113-9. doi: 10.3109/01480540903390000. [PubMed:20307139 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 09, 2016 03:14